<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cytokine Growth Factor Rev</journal-id><journal-id journal-id-type="iso-abbrev">Cytokine Growth Factor Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Cytokine &amp; Growth Factor Reviews</journal-title></journal-title-group><issn pub-type="ppub">1359-6101</issn><issn pub-type="epub">1879-0305</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7706592</article-id><article-id pub-id-type="pmcid-ver">PMC7706592.1</article-id><article-id pub-id-type="pmcaid">7706592</article-id><article-id pub-id-type="pmcaiid">7706592</article-id><article-id pub-id-type="pmid">33293238</article-id><article-id pub-id-type="doi">10.1016/j.cytogfr.2020.11.001</article-id><article-id pub-id-type="pii">S1359-6101(20)30227-6</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2: Targeted managements and vaccine development</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name name-style="western"><surname>Bakhiet</surname><given-names initials="M">Moiz</given-names></name></contrib><contrib contrib-type="author" id="aut0010"><name name-style="western"><surname>Taurin</surname><given-names initials="S">Sebastien</given-names></name><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005">Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Bahrain</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#8270;</label>Corresponding author.</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>1</day><month>12</month><year>2020</year></pub-date><volume>58</volume><issue-id pub-id-type="pmc-issue-id">369810</issue-id><fpage>16</fpage><lpage>29</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2020</year></date><date date-type="rev-recd"><day>23</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-23 02:25:38.447"><day>23</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="graphical" id="abs0005"><title>Graphical abstract</title><fig id="fig0025" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1_lrg.jpg"/></fig></abstract><abstract id="abs0015"><p>Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in diverse outcomes. The symptoms appear to be more severe in males older than 65 and people with underlying health conditions; approximately one in five individuals could be at risk worldwide. The virus&#8217;s sequence was rapidly established days after the first cases were reported and identified an RNA virus from the Coronaviridae family closely related to a Betacoronavirus virus found in bats in China. SARS-CoV-2 is the seventh coronavirus known to infect humans, and with the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), the only ones to cause severe diseases. Lessons from these two previous outbreaks guided the identification of critical therapeutic targets such as the spike viral proteins promoting the virus&#8217;s cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor expressed on the surface of multiple types of eukaryotic cells. Although several therapeutic agents are currently evaluated, none seems to provide a clear path for a cure. Also, various types of vaccines are developed in record time to address the urgency of efficient SARS-CoV-2 prevention. Currently, 58 vaccines are evaluated in clinical trials, including 11 in phase III, and 3 of them reported efficacy above 90 %. The results so far from the clinical trials suggest the availability of multiple effective vaccines within months.</p></abstract><kwd-group id="kwd0005"><title>Abbreviations</title><kwd>ACE2, angiotensin-converting enzyme II</kwd><kwd>ARDS, acute respiratory distress syndrome</kwd><kwd>DC-SIGN, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin</kwd><kwd>FDA, Food and Drug Administration</kwd><kwd>GCSF, granulocyte colony-stimulating factor</kwd><kwd>IL, interleukin</kwd><kwd>IP10, interferon &#947;-induced protein 10 kDa</kwd><kwd>L-SIGN, liver/lymph node-specific Intercellular adhesion molecule-3 grabbing non-integrin</kwd><kwd>MCP-1, monocyte Chemoattractant Protein-1</kwd><kwd>MERS, Middle East respiratory syndrome</kwd><kwd>MIP-1&#945;, macrophage inflammatory protein 1&#945;</kwd><kwd>ORFs, open reading frames</kwd><kwd>RANTES, Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted</kwd><kwd>RdRp, RNA-dependent RNA polymerase</kwd><kwd>SARS, severe acute respiratory syndrome</kwd><kwd>SARS-CoV, severe acute respiratory syndrome coronavirus</kwd><kwd>SARS-CoV-2, severe acute respiratory syndrome coronavirus-2</kwd><kwd>TH1, Type 1 T helper T-cell</kwd><kwd>TLR, Toll-like receptor</kwd><kwd>TMPRSS2, transmembrane serine protease 2</kwd><kwd>TNF-&#945;, tumor necrosis factor-&#945;</kwd><kwd>WHO, World Health Organization</kwd></kwd-group><kwd-group id="kwd0010"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Cytokines</kwd><kwd>Chemokines</kwd><kwd>Immunity</kwd><kwd>Spike protein</kwd><kwd>ACE2</kwd><kwd>Vaccines</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0030">Nearly a year since the first report of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cases in the Wuhan province in China, over 57 million cases have been diagnosed, and over 1.37 million have died worldwide as of November 22, 2020 [<xref rid="bib0005" ref-type="bibr">1</xref>]. Some countries have managed to control the disease&#8217;s spread by acting early, promoting contact tracing, encouraging self-distancing, and asking people to wear a mask in public. However, the last few weeks have seen the emergence of a second wave of hospitalization in the United States, Brazil, Argentina, and a few European countries. The sharp increase in Europe forced some states to implement a second partial lockdown. Other parts of the world, such as Iran, Sri Lanka, Philippines, continue to observe a steady increase in the number of new cases, while others continue to register the same numbers or a decrease in reported cases and COVID-19 associated deaths [<xref rid="bib0005" ref-type="bibr">1</xref>]. It is now clear that the disease will only be contained when an efficient therapy or vaccine will become available. This review gives a brief overview of the characteristics of SARS-CoV-2, the pathophysiology of the infection, the treatments currently tested, and vaccines developed.</p></sec><sec id="sec0010"><label>2</label><title>SARS-CoV-2 origin</title><p id="par0035">SARS-CoV-2 belongs to the <italic toggle="yes">Betacoronavirus</italic> genus, a group of related RNA viruses that can cause fatal respiratory tract infections. This genus includes the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS, and SARS-CoV-2 [<xref rid="bib0010" ref-type="bibr">2</xref>]. Only four common mildly pathogenic coronaviruses are endemic to humans, including HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E [<xref rid="bib0015" ref-type="bibr">3</xref>]. Both MERS and SARS-CoV are zoonotic pathogens transmitted to humans from intermediate hosts such as dromedary camels and civet cats, respectively [<xref rid="bib0020" ref-type="bibr">4</xref>,<xref rid="bib0025" ref-type="bibr">5</xref>]. The origin of SARS-CoV-2 is still debated, but the most closely related viruses originate from bats such as the RaTG13 virus, sharing &#8764; 96 % sequence homology, and isolated from the <italic toggle="yes">Rhinolophus affinis</italic> (<italic toggle="yes">i.e</italic>., intermediate horseshoe) bat [<xref rid="bib0030" ref-type="bibr">6</xref>]. Also, bats are the likely reservoir hosts of SARS-CoV-2; it is also imaginable that other mammalian species in close contact with the human population acted as intermediaries or amplifiers and prompted the zoonotic transfers [<xref rid="bib0035" ref-type="bibr">7</xref>]. Another plausible theory for the emergence of this virus is the asymptomatic natural selection of the virus in the human population following an initial zoonotic transmission and the acquisition of the critical mutations that improved its compatibility with humans [<xref rid="bib0040" ref-type="bibr">8</xref>]. The likelihood of these scenarios will require extensive sampling of wildlife and human populations in Wuhan, China.</p></sec><sec id="sec0015"><label>3</label><title>SARS-CoV-2 genome</title><p id="par0040">Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome packaged by nucleocapsid phosphoproteins [<xref rid="bib0045" ref-type="bibr">9</xref>]. Coronaviruses are one of the largest RNA viruses (26&#8722;32 kb); the SARS-CoV-2 genome varies from 29.8&#8211;29.9 kb and shares 79.6 and 50 % homology with SARS-CoV and MERS, respectively [<xref rid="bib0050" ref-type="bibr">10</xref>]. The SARS-CoV genome comprises 14 open reading frames (ORFs) encoding 27 proteins [<xref rid="bib0055" ref-type="bibr">11</xref>]. The first ORF (ORF1a and ORF1b) represents nearly 70 % of the virus genome and encompassed 15 nonstructural proteins (nsps) (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>
A) [<xref rid="bib0055" ref-type="bibr">11</xref>]. The remaining ORFs in the 3&#8217;-terminal region encoded for four structural proteins, namely membrane (M), envelope (E), spike (S) and nucleocapsid (N) proteins (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>B) and eight accessories proteins (3a, 3b, p6, 7a, 7b, 8b, 9b, and ORF14) (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>A) [<xref rid="bib0055" ref-type="bibr">11</xref>]. The S protein is composed of two subunits; S<sub>1</sub> holds the receptor-binding domain (RBD), which binds to a receptor on the host cell&#8217;s surface, while S<sub>2</sub> is needed for the fusion of the virus with the cellular membrane host [<xref rid="bib0060" ref-type="bibr">12</xref>]. In the inner side of the envelope, the nucleocapsid (N) proteins are bound to the positive-sense single-stranded RNA genome [<xref rid="bib0065" ref-type="bibr">13</xref>]. SARS-CoV-2 is characterized by a low mutation rate (6.7 mutations per sample) when comparing to a reference genome from Wuhan (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NC_045512.2">NC_045512.2</ext-link>) [<xref rid="bib0070" ref-type="bibr">14</xref>,<xref rid="bib0075" ref-type="bibr">15</xref>]. The phylogenic analysis of the genomic RNA sequences shared by the public database of the Global Initiative on Sharing All Influenza Data (GISAID) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gisaid.org/" id="intr0005">https://www.gisaid.org/</ext-link>) grouped SARS-CoV-2 into several distinctive viral clades characterized by specific mutations. Each clade clusters related sequences that refer to a common ancestor. For example, the substitution of aspartic acid by glycine at position 614 (D614 G) in the spike protein is the most frequently sequenced in a clade observed predominantly in Europe [<xref rid="bib0075" ref-type="bibr">15</xref>]. However, no experimental evidence demonstrated a biological difference acquired by the mutations, suggesting that a single strain of the SARS-CoV-2 virus is currently present.<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Genome organization, protein function, and structure of SARS-CoV-2. (A) Genome organization and protein function of SARS-CoV-2. ORF1a and 1b at the 5&#697; untranslated region are coding for polyproteins (pp1a/ab) cleaved in several nonstructural proteins (nsps) required for virus replication, followed by structural proteins for spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. At the 3&#697; terminus, accessory genes (3a, 3b, p6, 7a, 7b, 8b, 9b, and orf14) are located. The putative functions of these proteins are mentioned in the tables. (B) Structure of the SARS-CoV-2. The viral structural proteins S, M, E, and N are embedded in the membrane, while N proteins package the RNA. IFN, interferon; nsps, nonstructural proteins; ORF, open reading frame; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, RdRp, RNA-dependent RNA polymerase. Adapted from [<xref rid="bib0015" ref-type="bibr">3</xref>,<xref rid="bib0850" ref-type="bibr">[170]</xref>, <xref rid="bib0855" ref-type="bibr">[171]</xref>, <xref rid="bib0860" ref-type="bibr">[172]</xref>, <xref rid="bib0865" ref-type="bibr">[173]</xref>, <xref rid="bib0870" ref-type="bibr">[174]</xref>].</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p></sec><sec id="sec0020"><label>4</label><title>Life cycle of the virus</title><p id="par0045">Viruses are obligate intracellular parasites and the SARS-CoV-2 life cycle debuts when the transmembrane S structural glycoprotein binds to its receptor, angiotensin-converting enzyme 2 (ACE2), on the host cell [<xref rid="bib0080" ref-type="bibr">16</xref>]. ACE2 was also identified as a functional receptor for SARS-CoV and human coronavirus NL63 [<xref rid="bib0085" ref-type="bibr">17</xref>,<xref rid="bib0090" ref-type="bibr">18</xref>]. The RBD of the S1 subunit binds to the peptide domain of ACE2; this interaction triggers the priming of S1 at the S1/S2 junction by cellular proteases such as furin or endosomal proteases and exposes a secondary site (S2&#8217;) cleaved by the transmembrane serine protease 2 (TMPRSS2), which reveals the fusion peptide of the S2 subunit [<xref rid="bib0060" ref-type="bibr">12</xref>,<xref rid="bib0095" ref-type="bibr">19</xref>,<xref rid="bib0100" ref-type="bibr">20</xref>]. The cleavage modifies the conformation of the cleaved protein S irreversibly and allows the S2 subunit to insert into the host membrane and guide the fusion of the viral and cellular membranes [<xref rid="bib0060" ref-type="bibr">12</xref>]. Previous studies have reported the essential role of TMPRSS2 in the cellular entry of SARS-CoV-2, as well as SARS-CoV and MERS [<xref rid="bib0105" ref-type="bibr">[21]</xref>, <xref rid="bib0110" ref-type="bibr">[22]</xref>, <xref rid="bib0115" ref-type="bibr">[23]</xref>, <xref rid="bib0120" ref-type="bibr">[24]</xref>]. Hoffmann et al. demonstrated that camostat mesylate, an inhibitor of TMPRSS2, partially blocked the cellular entry of SARS-CoV-2 <italic toggle="yes">in vitro</italic> [<xref rid="bib0060" ref-type="bibr">12</xref>]. In addition to ACE2, CD147 was mentioned as a potential transmembrane receptor to mediate the cellular entry of SARS-CoV-2 [<xref rid="bib0125" ref-type="bibr">25</xref>]. CD147, also known as basigin or extracellular matrix metalloproteinase inducer, is a transmembrane glycoprotein, a member of the immunoglobulin superfamily, expressed on the surface of red blood cells, lymphocytes, dendritic cells (DCs), monocytes, macrophages, and many tissues [<xref rid="bib0130" ref-type="bibr">26</xref>,<xref rid="bib0135" ref-type="bibr">27</xref>]. CD147 is a known target for malaria treatment, as anti-CD147 antibodies prevent the red blood cell invasion by the protozoan Plasmodium falciparum [<xref rid="bib0140" ref-type="bibr">28</xref>], which has also been shown to facilitate the cellular entry of various viruses, including HIV-1 [<xref rid="bib0145" ref-type="bibr">29</xref>] and measles virus [<xref rid="bib0150" ref-type="bibr">30</xref>]. Wang et al. demonstrated the direct interaction, and colocalization of protein S and CD147 and the blocking of CD147 by humanized anti-CD147 antibody (Meplazumab) decreased SARS-CoV-2 replication <italic toggle="yes">in vitro</italic> [<xref rid="bib0125" ref-type="bibr">25</xref>].</p><p id="par0050">The SARS-CoV-2 entry into the cells, similarly as for SARS-CoV, is achieved by receptor-mediated endocytosis [<xref rid="bib0155" ref-type="bibr">31</xref>]. The viral RNA is released in the cytoplasm, uncoated, and the translations of the ORF1a and 1b are initiated. ORFs 1a and 1b code for the polyproteins pp1a (nsp1-11) and pp1ab (nsp1-16), respectively, depending on a ribosomal (-1)-frameshift demonstrated in coronavirus 31 years ago [<xref rid="bib0160" ref-type="bibr">32</xref>]. The polyproteins processing is coordinated spatially and temporally by viral proteases such as M<sup>pro</sup> (nsp5) and PL<sup>pro</sup> (nsp3) into nsps involved in the replication/transcription complex [<xref rid="bib0165" ref-type="bibr">33</xref>,<xref rid="bib0170" ref-type="bibr">34</xref>]. The nsps rearranged portion of the membrane derived from the rough endoplasmic reticulum into vesicles where the viral assembly is organized [<xref rid="bib0175" ref-type="bibr">35</xref>]. Viruses are then released from the host cell by exocytosis via secretory vesicles [<xref rid="bib0180" ref-type="bibr">36</xref>].</p></sec><sec id="sec0025"><label>5</label><title>Pathophysiology</title><p id="par0055">The pathophysiology of SARS-CoV-2 is similar to that observed with SARS-CoV and mainly affects the respiratory system, but other organs may be involved [<xref rid="bib0185" ref-type="bibr">[37]</xref>, <xref rid="bib0190" ref-type="bibr">[38]</xref>, <xref rid="bib0195" ref-type="bibr">[39]</xref>, <xref rid="bib0200" ref-type="bibr">[40]</xref>]. The presenting symptoms are a fever with dry cough and dyspnea [<xref rid="bib0190" ref-type="bibr">38</xref>] accompanied by headaches, dizziness, muscle pain, joint pain, and fatigue with gastrointestinal symptoms, including vomiting and diarrhea [<xref rid="bib0195" ref-type="bibr">39</xref>]. A multisystem inflammatory syndrome related to SARS-CoV-2 has been reported in older children and associated with severe abdominal pain, cardiac dysfunction, and shock, bearing similarities with the Kawasaki disease [<xref rid="bib0205" ref-type="bibr">41</xref>].</p><p id="par0060">Like SARS-CoV and MERS, respiratory droplets are the primary source of transmission of SARS-CoV-2 from human to human. The similarities of SARS-CoV-2 with SARS-CoV and MERS also suggest the possibility of fecal-oral transmission that remains unproven [<xref rid="bib0210" ref-type="bibr">42</xref>]. The median incubation period of SARS-CoV-2 varies from 4 to 6 days before developing symptoms [<xref rid="bib0185" ref-type="bibr">37</xref>,<xref rid="bib0215" ref-type="bibr">[43]</xref>, <xref rid="bib0220" ref-type="bibr">[44]</xref>, <xref rid="bib0225" ref-type="bibr">[45]</xref>]. Several studies reported a high viral load before or on symptom onset similarly to influenza, suggesting a high transmission potential even with mildly symptomatic cases; this appears to differ from the observation made with SARS-CoV showing a delayed peak of the viral load of several days following the symptoms&#8217; onset [<xref rid="bib0230" ref-type="bibr">[46]</xref>, <xref rid="bib0235" ref-type="bibr">[47]</xref>, <xref rid="bib0240" ref-type="bibr">[48]</xref>, <xref rid="bib0245" ref-type="bibr">[49]</xref>].</p><p id="par0065">Patients infected with SARS-CoV-2 may have minimal symptoms or experience acute respiratory distress syndrome (ARDS) with uncontrolled inflammation that may lead to multiple organ failures. Most patients with mild symptoms showed ground-glass opacity on chest computed tomography (CT) on admission [<xref rid="bib0185" ref-type="bibr">37</xref>]. Similar to SARS-CoV and MERS, the severity of the symptoms is strongly associated with the patients&#8217; age that may be explained by a weaker or dysregulated immune system [<xref rid="bib0185" ref-type="bibr">37</xref>,<xref rid="bib0190" ref-type="bibr">38</xref>,<xref rid="bib0250" ref-type="bibr">50</xref>].</p><p id="par0070">SARS-CoV-2 is a cytopathic virus that kills the cells and damages the tissue host as part of its replication cycle [<xref rid="bib0255" ref-type="bibr">51</xref>]. ACE2 was described as the primary receptor promoting the cellular entry of SARS-CoV-2 [<xref rid="bib0080" ref-type="bibr">16</xref>]. ACE2 is highly expressed on the alveolar epithelial type II cells&#8217; surface, critical for the lungs&#8217; gas exchange function preventing the alveoli from collapsing [<xref rid="bib0260" ref-type="bibr">52</xref>]. However, ACE2 is also present on the surface of type I pneumocytes, endothelial cells, and in extrapulmonary tissues, including heart, intestine, blood vessels, kidneys, and urinary bladder [<xref rid="bib0265" ref-type="bibr">53</xref>,<xref rid="bib0270" ref-type="bibr">54</xref>]. The alveolar epithelial type II cells were also described as a potential viral reservoir that may disseminate the virus to other organs and individuals [<xref rid="bib0270" ref-type="bibr">54</xref>,<xref rid="bib0275" ref-type="bibr">55</xref>]. The epithelial cell death following viral infection has been associated with apoptosis and a pro-inflammatory program cell death named pyroptosis, which triggers the release of pro-inflammatory cytokines, for example, interleukin-1&#946; (IL-1&#946;) and IL-18 (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>
A-B) [<xref rid="bib0280" ref-type="bibr">56</xref>,<xref rid="bib0285" ref-type="bibr">57</xref>]. Previous studies have reported the increased level of pro-inflammatory cytokines in patients infected with SARS-CoV-2, including IL-1&#946;, IL-6, IL-8, TNF-&#945;, IP10, MCP-1, and RANTES [<xref rid="bib0190" ref-type="bibr">38</xref>,<xref rid="bib0290" ref-type="bibr">58</xref>] (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>C). Studies on SARS-CoV and MERS also reported the elevation of pro-inflammatory cytokines in patients&#8217; serum and their association with pulmonary inflammation and extensive lung damage (for review, see [<xref rid="bib0190" ref-type="bibr">38</xref>]). The secretion of cytokines and chemokines recruit monocytes and macrophages, which release cytokines to prime T-cell adaptive immune response. In most patients, the immune cells&#8217; recruitment will clear the virus, and inflammation will recede. However, in a few patients with a weak immune system and/or other unknown preexisting conditions, an uncontrolled inflammatory response linked to a cytokine storm, characterized by the increased plasma level of IL-2, IL-7, IL-10, GCSF, IP-10, MCP-1, MIP-1&#945;, and TNF-&#945;, has been associated with the severity of the pulmonary inflammation, and likely the leading cause of death (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>D) [<xref rid="bib0190" ref-type="bibr">38</xref>].<fig id="fig0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Infection of the alveolar epithelial type II cells by the SARS-CoV-2. (A) SARS-CoV-2 targets cells expressing angiotensin-converting enzyme 2 (ACE2). (B) The virus is endocytosed. The transmembrane serine protease 2 (TMPRSS2) cleaved the S proteins to allow the viral RNA into the host cell cytoplasm. The replication of the virus triggers pyroptosis and the release of DNA, ATP, IL-1&#946;, and other factors. (C) The factors are recognized by the neighboring cells and resident alveolar macrophages, promoting the secretion of pro-inflammatory cytokines and chemokines, including IL-6, IL-8, TNF-&#945;, IP10, MCP-1, and RANTES. These factors attract monocytes and dendritic cells, amplifying the signal. (D) These signals lure T-cells and more immune cells that, in a defective immune response, trigger a cytokine storm damaging the lungs and affecting other organs. IL, interleukin; IP10, interferon-&#947;-inducible protein; MCP-1, monocyte chemoattractant protein-1; MIP-1&#945;, macrophage inflammatory protein 1&#945;; GCSF, granulocyte colony-stimulating factor; TNF, tumor necrosis factor; RANTES, regulated on activation, normal T-cell expressed and secreted.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p><p id="par0075">As described above, epithelial cells, macrophages of the alveoli, and DCs underneath the epithelium are the main components for the innate immunity to the virus [<xref rid="bib0295" ref-type="bibr">59</xref>]. Antigen presentation by DCs and macrophages will initiate the T-cell responses. SARS-CoV-2 enters these cells either by phagocytosis of apoptotic cells infected by virus-like epithelial cells [<xref rid="bib0300" ref-type="bibr">60</xref>] or via pattern recognition receptors (PRRs) [<xref rid="bib0305" ref-type="bibr">61</xref>]. The SARS-CoV-2 may also use the ACE2, expressed in macrophages and DCs [<xref rid="bib0310" ref-type="bibr">62</xref>,<xref rid="bib0315" ref-type="bibr">63</xref>]. The SARS-CoV-2 virus may bind to the dendritic cell intercellular adhesion molecules 3-grabbing non-integrin (DC-SIGN), and L-SIGN [<xref rid="bib0320" ref-type="bibr">[64]</xref>, <xref rid="bib0325" ref-type="bibr">[65]</xref>, <xref rid="bib0330" ref-type="bibr">[66]</xref>]. These APCs then present viral antigens to T-cells. CD4<sup>+</sup> and CD8<sup>+</sup> T-cell in the draining lymph nodes. CD4<sup>+</sup> T-helper cells induce and help B-cells to produce the virus-specific antibody. The cytotoxic CD8<sup>+</sup> T-cells can kill virally infected cells. It has been observed in patients with severe diseases a storm of pro-inflammatory cytokines, mainly IL-6, TNF-&#945;, G-CSF in addition to the anti-inflammatory cytokine IL-10 and the chemokines MCP-1, MIP-1&#945;, and IL-8, but the more severe disease was noted with higher levels of IL-6 [<xref rid="bib0190" ref-type="bibr">38</xref>,<xref rid="bib0335" ref-type="bibr">[67]</xref>, <xref rid="bib0340" ref-type="bibr">[68]</xref>, <xref rid="bib0345" ref-type="bibr">[69]</xref>]. In the patients never exposed to SARS-CoV-2, the T-cells&#8217; cross-reactivity was detected in 20 % of the cases, probably due to previous exposure to common cold coronaviruses [<xref rid="bib0350" ref-type="bibr">70</xref>]. Specific T-cells against the proteins S, M, and N were detected in the peripheral blood mononuclear cells from convalescent SARS-CoV-2 patients [<xref rid="bib0355" ref-type="bibr">71</xref>]. Furthermore, CD4<sup>+</sup> T-cells showed strong reactivity against M and S proteins, mostly in mild SARS-CoV-2 patients [<xref rid="bib0360" ref-type="bibr">72</xref>]. In severe SARS-CoV-2 cases, CD4<sup>+</sup> with memory phenotype and CD8<sup>+</sup> T-cells with effector phenotype were detected in the blood [<xref rid="bib0350" ref-type="bibr">70</xref>]. Further studies will be required to understand the T-cells&#8217; involvement in the progression of severe SARS-CoV-2 symptoms.</p><p id="par0080">Furthermore, thrombosis and pulmonary embolism have been observed in severe SARS-CoV-2 diseases [<xref rid="bib0365" ref-type="bibr">73</xref>]. Platelets were hyperactivated, and aggregation occurred at thrombin suboptimal concentrations [<xref rid="bib0370" ref-type="bibr">74</xref>]. This may be due to the massive inflammation enhancing cytokines and increasing the liver&#8217;s production of clotting factors. Furthermore, the cytokine TNF-&#945; highly produced in SARS-CoV-2 has been implicated in promoting overexpression of tissue factor (TF) in platelets and macrophages [<xref rid="bib0375" ref-type="bibr">75</xref>]. TF acts as a receptor and cofactor for coagulation factors VII and VIIa [<xref rid="bib0380" ref-type="bibr">76</xref>,<xref rid="bib0385" ref-type="bibr">77</xref>]. Thus, the cytokine-induced TF synthesis and release can significantly impact the coagulation responses [<xref rid="bib0390" ref-type="bibr">78</xref>]. Another mechanism noted in the pathogenesis of COVID-19 is the interaction with hemoglobin via CD147 and CD26 expressed on erythrocytes [<xref rid="bib0395" ref-type="bibr">79</xref>].</p><p id="par0085">The immune response and associated molecular events to SARS-CoV-2 infection remain poorly understood; it is critical to identify these elements to direct an efficient therapeutic approach. A recent study reported that individuals previously infected with COVID-19, which triggered an antibody, was sufficient to protect most individuals from reinfection in the six months following infection; the long term protection remains to be determined [<xref rid="bib0400" ref-type="bibr">80</xref>].</p></sec><sec id="sec0030"><label>6</label><title>Therapeutic approaches</title><p id="par0090">According to the World Health Organization (WHO), there are no specific medicines or vaccines for SARS-CoV-2. In the early days of the pandemic, many governments worldwide have to some degree implemented measures recommended by WHO to limit the spread of the virus such as self-isolation, social distancing, hand washing, closure of schools and universities, and wearing a mask in public places [<xref rid="bib0405" ref-type="bibr">81</xref>]. These measures proved to be efficient, when followed, and saved countless lives [<xref rid="bib0410" ref-type="bibr">82</xref>].</p><p id="par0095">Several medications are currently evaluated in clinical trials; 3947 clinical trials are presently listed on clinicaltrials.gov, including 490 phase-III and 104 phase IV clinical trials as of November 19, 2020. The management provided to the patients is mainly supportive and critical for at least 5% of patients developing severe symptoms and requiring hospitalization [<xref rid="bib0410" ref-type="bibr">82</xref>]. Available drugs have been repurposed for the treatment of SARS-CoV2, including lopinavir-ritonavir, remdesivir, favipiravir, arbidol, chloroquine and analogs hydroxychloroquine, and azithromycin and tested in clinical trials [<xref rid="bib0415" ref-type="bibr">[83]</xref>, <xref rid="bib0420" ref-type="bibr">[84]</xref>, <xref rid="bib0425" ref-type="bibr">[85]</xref>, <xref rid="bib0430" ref-type="bibr">[86]</xref>, <xref rid="bib0435" ref-type="bibr">[87]</xref>]. However, results were not very promising for any of them to be a definite therapy yet. <xref rid="fig0015" ref-type="fig">Fig. 3</xref>
schematized some of the various therapeutic strategies presently assessed in various clinical trials.<fig id="fig0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Therapeutics trialed for the treatment of SARS-CoV-2. Repurposed and investigational drugs were assessed in various clinical trials, either as single-drug treatment or combinations. ACE2: angiotensin-converting enzyme 2; TMPRSS2, transmembrane serine protease 2; nsps, nonstructural proteins; pp1a; polyprotein 1a; pp1ab; polyprotein 1ab; RdRp, RNA-dependent RNA polymerase; IL-6, interleukin-6.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig></p><sec id="sec0035"><label>6.1</label><title>Inhibitors of virus entry</title><sec id="sec0040"><label>6.1.1</label><title>Arbidol</title><p id="par0100">Arbidol, an anti-influenza virus drug, was also efficient in inhibiting SARS-CoV-2 infection in vitro [<xref rid="bib0440" ref-type="bibr">88</xref>]. Arbidol prevents the interaction between ACE2 and the viral protein S by blocking its trimerization of the viral protein S [<xref rid="bib0445" ref-type="bibr">89</xref>]. In a small non-randomized controlled study, arbidol showed a tendency to improve recovery and decrease mortality [<xref rid="bib0450" ref-type="bibr">90</xref>]. A comparison of the safety and efficacy of arbidol or lopinavir/ritonavir to the standard of care in a phase IV interventional clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04252885">NCT04252885</ext-link>) showed little benefit of both treatment regimen for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over the standard of care [<xref rid="bib0455" ref-type="bibr">91</xref>]. However, further power randomized placebo-controlled studies are required to validate these observations.</p></sec><sec id="sec0045"><label>6.1.2</label><title>Recombinant soluble form of human ACE2</title><p id="par0105">A similar initiative trying to block the interaction between the viral protein S and ACE2 is currently evaluated in a phase I clinical trial using a recombinant soluble form of human ACE2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00886353">NCT00886353</ext-link>) based on the previous clinical trial demonstrating its safety [<xref rid="bib0460" ref-type="bibr">92</xref>]. In a case report, a 45-year-old woman infected by SARS-CoV-2 initially received hydroxychloroquine (400 mg twice daily) and anticoagulant nadroparin (4 mg once daily); as her condition worsened, she was intubated. On the 9th day after the onset of symptoms, she was given human recombinant soluble ACE2 (APN01; 0&#183;4 mg/kg, i.v., twice daily) [<xref rid="bib0465" ref-type="bibr">93</xref>]. After 7 days, the treatment was well-tolerated, and her condition improved gradually; she was extubated on day 21. The recombinant soluble ACE2 decreased the plasma concentration of angiotensin II while promoting the increase of its metabolites&#8217; angiotensin 1&#8211;7 and angiotensin 1&#8211;5, and cleaving angiotensin I into angiotensin 1&#8211;9 [<xref rid="bib0465" ref-type="bibr">93</xref>]. Angiotensin II is elevated in lung injury and is associated with worsening conditions such as hypertension, diabetes, inflammation, and affecting the physiology of the heart, lungs, kidneys, vasculature, and liver [<xref rid="bib0465" ref-type="bibr">93</xref>]. The treatment was also associated with a decrease of pro-inflammatory cytokines (IL-6 and IL-8) and other inflammation markers (TNF-&#945;, ferritin) [<xref rid="bib0465" ref-type="bibr">93</xref>].</p></sec><sec id="sec0050"><label>6.1.3</label><title>Chloroquine and analog hydroxychloroquine</title><p id="par0110">Chloroquine and analogs hydroxychloroquine act as viral entry inhibitors; by increasing endosomal pH required for virus/cell fusion and interfering with the cellular receptors&#8217; glycosylation for SARS-CoV-2 (ACE-2) [<xref rid="bib0470" ref-type="bibr">94</xref>]. In contrast to the early reports of poorly controlled studies, chloroquine and analogs hydroxychloroquine failed to demonstrate any benefit for treating this disease (for review, see [<xref rid="bib0475" ref-type="bibr">95</xref>]). The interim report of WHO solidarity trial involving 11,266 hospitalized COVID-19 patients involving 405 hospitals in 30 countries assessed the efficacy of four repurposed antiviral drugs, including remdesivir (intravenous, day 0: 200 mg, day 1 to 9: 100 mg), hydroxychloroquine (oral, 800 mg twice over 6 h, then 400 mg twice daily for 10 days), lopinavir/ritonavir (oral, 400 mg lopinavir +1 g ritonavir twice daily for 14 days), and interferon-&#946;1a (subcutaneous, 3 doses 44 &#956;g over 6 days or intravenous., 10 &#956;g once daily over 6 days) (WHO registration: ISRCTN83971151, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04315948">NCT04315948</ext-link>). Overall, most patients hospitalized were aged between 50&#8211;69 years (45 %) and had underlying conditions including diabetes (25 %), heart disease (21 %), chronic lung disease (6%), asthma (5%), and chronic liver disease (1%) [<xref rid="bib0480" ref-type="bibr">96</xref>]. The report concluded that remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon-&#946;1a had little to no effect on COVID-19 patients as measured by the overall death, placement under ventilation, or duration of hospitalization [<xref rid="bib0480" ref-type="bibr">96</xref>].</p></sec></sec><sec id="sec0055"><label>6.2</label><title>Inhibitor of proteolysis</title><p id="par0115">Lopinavir-ritonavir, a combination medication used for HIV/AIDS treatment, is a protease inhibitor that inhibits viral protein synthesis, potentially targeting the SARS-CoV-2 viral protease M<sup>pro</sup> essential for the replication. Lopinavir-ritonavir also demonstrated efficacy <italic toggle="yes">in vitro</italic>, inhibiting SARS-CoV-2 replication [<xref rid="bib0485" ref-type="bibr">97</xref>]. The combination failed to procure any benefit beyond standard care in clinical trials [<xref rid="bib0490" ref-type="bibr">98</xref>,<xref rid="bib0495" ref-type="bibr">99</xref>].</p></sec><sec id="sec0060"><label>6.3</label><title>Inhibitors of the viral RNA-dependent RNA polymerase</title><p id="par0120">Remdesivir (adenosine analog prodrug) and Favipiravir (guanine analog prodrug) act as inhibitors of the viral RNA-dependent RNA polymerase (RdRp), demonstrated potent antiviral activity <italic toggle="yes">in vitro</italic> [<xref rid="bib0470" ref-type="bibr">94</xref>,<xref rid="bib0500" ref-type="bibr">100</xref>,<xref rid="bib0505" ref-type="bibr">101</xref>].</p><sec id="sec0065"><label>6.3.1</label><title>Favipiravir</title><p id="par0125">Favipiravir was approved for the treatment of SARS-CoV-2 in Russia and India and currently assessed in many countries. The drug is given orally and improves the patients&#8217; conditions in the clinic compared to the standard of care but no significant difference in viral clearance, the requirement for oxygen support, and side effect profile [<xref rid="bib0510" ref-type="bibr">102</xref>]. In an open-label clinical trial (ChiCTR2000029600), COVID-19 patients were treated with favipiravir (1600 mg twice daily on Day 1 and 600 mg twice daily on days 2&#8211;14, orally) or lopinavir-ritonavir (400 mg/100 mg twice daily orally). All patients received interferon (IFN)-&#945; by aerosol inhalation (5 &#215; 10<sup>6</sup> international unit twice daily [<xref rid="bib0515" ref-type="bibr">103</xref>]. The favipiravir group had an early viral clearance (median 4 days) compared to patients treated with lopinavir-ritonavir (median 11 days); the chest CT findings were improved in the favipiravir group at day 14 (91.4 % vs. 62,2 %) [<xref rid="bib0515" ref-type="bibr">103</xref>]. The patients experienced a lower incidence of side effects in the favipiravir group (11.4 % vs. 55.6 %) [<xref rid="bib0515" ref-type="bibr">103</xref>]. Another clinical trial (ChiCTR2000030254) compared favipiravir treatment (1600 mg twice a day on the first day followed by 600 mg twice a day for 10 days) to arbidol (200 mg three times per day for 10 days) [<xref rid="bib0520" ref-type="bibr">104</xref>]. Clinically confirmed patients and not the virally confirmed ones were allocated randomly to each group; only 46.5 and 38.3 % of patients were nucleic acid positive at enrollment in the favipiravir and arbidol group, respectively [<xref rid="bib0520" ref-type="bibr">104</xref>]. The clinical recovery rate and auxiliary oxygen therapy or noninvasive mechanical ventilation did not significantly differ between the two groups; favipiravir tended to relieve adverse effects more rapidly [<xref rid="bib0520" ref-type="bibr">104</xref>]. Favipiravir is currently evaluated in 17 phase-III clinical trials. The data obtained for favipiravir in clinical trials are encouraging, but the completion of large, randomized double-blinded, placebo-controlled clinical trials will provide unbiased data.</p></sec><sec id="sec0070"><label>6.3.2</label><title>Remdesivir</title><p id="par0130">Remdesivir results in clinical trials were conflicting. Remdesivir failed to demonstrate any statistically significant clinical benefits for severe SARS-CoV-2 patients in a randomized, double-blind, placebo-controlled, multicentre trial in Wuhan, China, but underpowered (clinical trial: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04257656">NCT04257656</ext-link>) [<xref rid="bib0525" ref-type="bibr">105</xref>]. In a double-blind, randomized, placebo-controlled trial sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04280705">NCT04280705</ext-link>), patients received 200 mg on day 1, followed by 100 mg daily for up to 9 days given intravenously. Remdesivir was shown to improve the recovery time from 15 to 10 days for COVID-19 patients (rate ratio for recovery, 1.29 [95 % CI, 1.12&#8211;1.49]) [<xref rid="bib0530" ref-type="bibr">106</xref>]. Patients had preexisting conditions such as type 2 diabetes (30.6 %), hypertension (50.7 %), or obesity (45.6 %) [<xref rid="bib0530" ref-type="bibr">106</xref>]. However, no significant differences in survival were observed; mortality was decreased by 3.8 % in the remdesivir versus placebo groups (hazard ratio, 0.73; 95 % CI, 0.52&#8211;1.03) [<xref rid="bib0530" ref-type="bibr">106</xref>]. The Food and Drug Administration (FDA) approved remdesivir on October 22nd, 2020. More recently, following the WHO SOLIDARITY trial results, the WHO suggested against the use of Remdesivir for hospitalized patients with Covid-19 regardless of the severity [<xref rid="bib0535" ref-type="bibr">107</xref>].</p></sec><sec id="sec0075"><label>6.3.3</label><title>Avifavir</title><p id="par0135">More recently, avifavir, introduced as the first favipiravir-based drug, was approved for the treatment of SARS-COV-2 in Russia. An interim report of a phase II/III clinical trial of 60 hospitalized patients with mild COVID-19 symptoms randomized equally in three groups receiving avifavir 1600 mg twice on day 1 followed by 600 mg twice on days 2&#8211;14, or avifavir 1800 mg twice on day 1 followed by 800 mg twice on days 2&#8211;14, or standard of care as a control group [<xref rid="bib0540" ref-type="bibr">108</xref>]. Both avifavir dosages had a similar effect on viral clearance on day 5, which was achieved in 25/40 patients (62.5 %) compared to 6/20 patients treated by the standard of care [<xref rid="bib0540" ref-type="bibr">108</xref>]. Despite the small sample size, avifavir was granted fast-track marketing authorization by the Russian Ministry of Health [<xref rid="bib0540" ref-type="bibr">108</xref>].</p></sec></sec><sec id="sec0080"><label>6.4</label><title>Alternative strategies</title><sec id="sec0085"><label>6.4.1</label><title>Targeting host proteins and immune response modulators</title><p id="par0140">Alternative strategies targeting host proteins and immune response modulators are currently developed. Camostat mesylate and nafamostat mesylate target the TMPRSS2, an essential serine protease critical for the cellular entry of SARS-CoV-2 into the lung cells [<xref rid="bib0060" ref-type="bibr">12</xref>,<xref rid="bib0545" ref-type="bibr">109</xref>]. Both compounds are approved in Japan to treat pancreatitis and are currently assessed in several clinical trials for the treatment of SARS-CoV-2. Immunomodulators as Nitazoxanide were also used for interference with host-regulated pathways involved in viral replication, amplifying cytoplasmic RNA sensing, and type I IFN pathways [<xref rid="bib0505" ref-type="bibr">101</xref>].</p></sec><sec id="sec0090"><label>6.4.2</label><title>Targeting inflammation and coagulation</title><p id="par0145">In severe cases of SARS-CoV-2, anti-inflammatory and anti-Coagulative agents have been proposed and implemented because of the profound inflammatory response and the thrombotic phenomena described in the lungs of patients with severe SARS-COV-2, including administration of low-molecular-weight heparin as a standard measure in hospitalized patients with SARS-CoV-2 [<xref rid="bib0550" ref-type="bibr">110</xref>].</p><p id="par0150">IL-6 is an inflammatory cytokine targeted in neutralizing therapies in several inflammatory diseases [<xref rid="bib0555" ref-type="bibr">111</xref>]. Increased serum concentrations of IL-6 were noted during severe infections with Coronavirus SARS-CoV-2, suggesting possible implications for anti-IL-6 therapy in SARS-CoV-2 disease [<xref rid="bib0560" ref-type="bibr">112</xref>]. Tocilizumab, an inhibitor of IL-6, might reduce the risk of invasive mechanical ventilation or death in patients with severe SARS-CoV-2 [<xref rid="bib0565" ref-type="bibr">113</xref>]. Tocilizumab is currently registered in 71 clinical trials for the treatment of SARS-CoV-2, a randomized double-blinded phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04320615">NCT04320615</ext-link>) compared tocilizumab (8 mg/kg, i.v.) to the standard of care in severe COVID-19 patients [<xref rid="bib0570" ref-type="bibr">114</xref>]. The outcome of the treatment was measured at day 28; also, tocilizumab did not improve the clinical status or mortality when compared to the standard of care; it decreased the stay in the intensive care unit by 5.8 days (9.8 days) and shorter the discharge time by 8 days (20 days) [<xref rid="bib0570" ref-type="bibr">114</xref>]. Additional clinical trials will be necessary to determine the advantage of tocilizumab on the duration of the hospitalization.</p></sec><sec id="sec0095"><label>6.4.3</label><title>Immunomodulation by glucocorticoids</title><p id="par0155">Glucocorticoids are also assessed in several clinical trials; their immunosuppressive effect requires careful consideration. It may influence the viral clearance, while their anti-inflammatory effect may limit the tissue damage induced by the cytokine storm and favor their use in severe COVID-19 cases [<xref rid="bib0575" ref-type="bibr">115</xref>]. A randomized, controlled clinical trial in the United Kingdom using dexamethasone in severely ill patients reduced deaths by about one-third of patients on ventilators [<xref rid="bib0580" ref-type="bibr">116</xref>,<xref rid="bib0585" ref-type="bibr">117</xref>]. The randomized evaluation of the COVID-19 therapy (RECOVERY) trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04381936">NCT04381936</ext-link>) demonstrated that a dose of dexamethasone (6 mg) once daily for up to 10 days reduced the mortality of patients under respiratory assistance but may be harmful to patients who do not require oxygen support [<xref rid="bib0590" ref-type="bibr">118</xref>]. The WHO has recently recommended the use of corticosteroids to treat hospitalized patients with severe and critical Covid-19 [<xref rid="bib0535" ref-type="bibr">107</xref>]. Additional glucocorticoids were evaluated in clinical trials, including methylprednisolone (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04343729">NCT04343729</ext-link>, 2020-001934-37, and IRCT20200404046947N1), hydrocortisone (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02735707">NCT02735707</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02517489">NCT02517489</ext-link>). Methylprednisolone Both clinical trials assessing hydrocortisone were stopped earlier for failing to meet the prespecified criteria for statistical superiority [<xref rid="bib0595" ref-type="bibr">119</xref>,<xref rid="bib0600" ref-type="bibr">120</xref>].</p></sec><sec id="sec0100"><label>6.4.4</label><title>Passive immunotherapy and neutralizing antibodies</title><p id="par0160">Passive immunotherapy using plasma from recovering patients was considered a promising option in the treatment of SARS-CoV-2 infections. The WHO and the FDA have permitted plasma therapy for severe conditions upon failure of trial medications. Several clinical trials are underway to test the effectiveness of hyperimmune plasma [<xref rid="bib0605" ref-type="bibr">121</xref>]. A recent study demonstrated that antibodies in the serum of patients infected with SARS-CoV effectively neutralized SARS-CoV-2 <italic toggle="yes">in vitro</italic> [<xref rid="bib0610" ref-type="bibr">122</xref>]. The administration of convalescent plasma to 5,000 COVID-19 hospitalized patients demonstrated to be safe as the occurrence of serious adverse events was low and likely to be beneficial when given at an early stage of the development of COVID-19 [<xref rid="bib0615" ref-type="bibr">123</xref>].</p><p id="par0165">LY-CoV555 (bamlanivimab, LY3819253), a neutralizing IgG1 monoclonal antibody that binds with high affinity to the SARS-CoV-2 spike protein, was isolated from some of the first patients in North America [<xref rid="bib0620" ref-type="bibr">124</xref>]. In a phase II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04427501">NCT04427501</ext-link>) sponsored by Eli Lilly and Company, patients received a single dose of either LY-CoV5555 at 700, 2,800, or 7,000 mg or placebo. Only the single intravenous infusion of LY-CoV555 (2,800 mg) appeared to accelerate the viral load&#8217;s natural decline [<xref rid="bib0620" ref-type="bibr">124</xref>]. The LY-CoV555 treated patients had fewer hospitalizations than the placebo group, 1.6 vs. 6.3 %, respectively, and 4.2 vs. 14.6 % when considering high-risk patients, respectively [<xref rid="bib0620" ref-type="bibr">124</xref>]. Eli Lilly has been granted emergency use on November 10, 2020, by the FDA, to treat mild to moderate Covid-19 adults and pediatric patients older than 12 years of age, weighing 40 kg, and at risk of developing severe Covid-19 and /or hospitalization.</p><p id="par0170">AZD7442 is a combination of two long-acting antibodies derived from convalescent patients after SARS-CoV-2 infection. The antibodies (COV2-2196 and COV2-2130), isolated by the Vanderbilt University Medical Center, recognized non-overlapping sites of the viral spike protein and were shown to neutralize the SARS-CoV-2 infection synergistically in two murine models [<xref rid="bib0625" ref-type="bibr">125</xref>]. These antibodies were licensed by AstraZeneca in June 2020 and modified to extend their half-life for 6&#8211;12 months and reduce the Fc receptor binding. AZD7442 entered phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04507256">NCT04507256</ext-link>) in August 2020. AstraZeneca started two phase III clinical trials in November 2020, Storm chaser (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04625972">NCT04625972</ext-link>, 1125 participants) and Provent (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04625725">NCT04625725</ext-link>, 5,000 participants). The Provent trial will evaluate the safety and efficacy for the prevention of SARS-CoV-2 infection for up to 12 months following a single injection, while the Storm Chaser trial will evaluate post-exposure prophylaxis and pre-emptive treatment following a single injection. Recently, the US government secured 100,000 doses of AZD7442.</p><p id="par0175">REGN-COV2, manufactured by Regeneron Pharmaceuticals, is a cocktail of two neutralizing synthetic antibodies, casirivimab (REGN10933) and imdevimab (REGN10987), targeting non-overlapping epitopes of the viral spike protein. On November 21st, 2020, REGN-COV2 received an emergency use authorization by the FDA to treat mild to moderate COVID-19 adults and pediatric patients older than 12 years of age, weighing 40 kg, and at high risk of developing severe COVID-19. This emergency use authorization includes subjects who are 65 years or older or who have chronic medical conditions. In a preclinical study, REGN-COV2 reduced the viral load in upper and lower airways when given as a prophylactic or as a treatment in rhesus macaques [<xref rid="bib0630" ref-type="bibr">126</xref>]. In an animal model of severe COVID-19, REGN-COV2 decreased the viral lung titers and evidence of pneumonia [<xref rid="bib0630" ref-type="bibr">126</xref>]. Regeneron Pharmaceuticals announced preliminary data from 275 patients in a phase I/II/III trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04425629">NCT04425629</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04426695">NCT04426695</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04452318">NCT04452318</ext-link>), showing that REGN-COV2 reduced viral load, alleviate symptoms in non-hospitalized patients infected with COVID-19, and decreased patient medical visits (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investor.regeneron.com/press-releases" id="intr0010">https://investor.regeneron.com/press-releases</ext-link>). For patients at high risk for disease progression, hospitalizations, and emergency room visits occurred in 3 % of the REGN-COV2 patients compared to 9 % of the placebo-treated patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/fda-newsroom/press-announcements" id="intr0015">https://www.fda.gov/news-events/fda-newsroom/press-announcements</ext-link>).</p><p id="par0180">Additional neutralizing antibodies are currently evaluated in multiple phase I clinical trials, including VIR-7831, 47D11, CT-P59, ALVR109, STI-1499, IVIG, and COVID-HIG (for review see [<xref rid="bib0635" ref-type="bibr">127</xref>].</p></sec></sec></sec><sec id="sec0105"><label>7</label><title>Vaccine strategy</title><p id="par0185">The genetic drifting of SARS-CoV-2 has been extremely slow [<xref rid="bib0640" ref-type="bibr">128</xref>], increasing the prospect of designing vaccines that will confer immunity to the global population against all viral clades. Although very few efficient vaccines are available for RNA viruses, in many cases and for certain technologic restrictions and economic issues, these vaccines are barely used, and many of them are not licensed. Vaccines against SARS-CoV were developed following the SARS outbreak in 2002&#8211;2003, and only two were assessed in phase I clinical trials using a recombinant DNA vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00099463">NCT00099463</ext-link>) [<xref rid="bib0645" ref-type="bibr">129</xref>]or an inactivated SARS-CoV vaccine [<xref rid="bib0650" ref-type="bibr">130</xref>]. As contact tracing and quarantine put an end to the transmission, no further SARS-CoV vaccine development was undertaken [<xref rid="bib0655" ref-type="bibr">131</xref>]. The outbreak of MERS in 2012 led to the development of several vaccines currently evaluated or recruiting in phase I clinical trials. The development of a vaccine is usually a lengthy process that could take over 15 years. Since the SARS-CoV-2 pandemic started, scientists worldwide are combining efforts, sharing data, and establishing collaboration to speed up a vaccine&#8217;s development in just a few months. Several governments, foundations, and companies have pledged partnerships and funding to accelerate the research for a vaccine, including the Accelerating COVID-19 Therapeutic Interventions and Vaccine [<xref rid="bib0660" ref-type="bibr">132</xref>]. Preclinical studies on SARS-CoV and MERS informed the best vaccine development strategies and identified key protein targets. The candidate vaccines&#8217; preclinical toxicology is accomplished in just a few months, followed by clinical trials with overlapping phases. Some manufacturers have already started the vaccine&#8217;s large-scale production to face the Brobdingnagian demand before completing phase III. Before developing a phase III clinical trial, Russia and China have granted early or limited approval, respectively. Cansino Biologics vaccine (Ad5-nCoV) is limited to the Chinese military use, and the Gamaleya Research Institute vaccine (Gam-COVID-Vac) in Russia was licensed and rebranded as Sputnik V in August 2020 without a phase III clinical trial. Currently, 261 vaccines are tested; most of the vaccines are in the preclinical phase of development, while 11 vaccines have entered phase III clinical trials (<xref rid="fig0020" ref-type="fig">Fig. 4</xref>
and <xref rid="tbl0005" ref-type="table">Table 1</xref>
) [<xref rid="bib0665" ref-type="bibr">133</xref>]. Various platforms have been exploited for the development of SARS-CoV-2 vaccines (<xref rid="fig0020" ref-type="fig">Fig. 4</xref>). Classical platforms include the whole inactivated virus, live attenuated virus, protein subunit, and virus-like particle and next-generation platforms where few vaccines have been licensed and include viral vector, antigen-presenting cells, DNA, and RNA.<fig id="fig0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Number and types of vaccines currently in the preclinical phase and the different clinical trial phases. Data were adapted from the COVID-19 vaccine tracker [<xref rid="bib0665" ref-type="bibr">133</xref>].</p></caption><alt-text id="at0020">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4_lrg.jpg"/></fig><table-wrap position="float" id="tbl0005" orientation="portrait"><label>Table 1</label><caption><p>Vaccines in phase III clinical trials. All clinical trials are randomized, placebo controlled, and double blind, and currently recruiting except for clinical trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link> which is not yet recruiting. All data were obtained from clinical trial.org and EU clinical trials register.</p></caption><alt-text id="at0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Vaccine</th><th align="left" colspan="1" rowspan="1">Platform</th><th align="left" colspan="1" rowspan="1">Sponsors</th><th align="left" colspan="1" rowspan="1">Number of Participants<break/>Age</th><th align="left" colspan="1" rowspan="1">Doses</th><th align="left" colspan="1" rowspan="1">Locations</th><th align="left" colspan="1" rowspan="1">Clinical Trial</th><th align="left" colspan="1" rowspan="1">Start Date - Estimated Completion Date (m/y)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">BNT162b2</td><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">BioNTech SE<break/>Pfizer</td><td align="left" colspan="1" rowspan="1">45,000<break/>&#8805; 16 years</td><td align="left" colspan="1" rowspan="1">2<break/>Separated by 21 days</td><td align="left" colspan="1" rowspan="1">166 locations:<break/>USA, Argentina, Brazil, South Africa, Turkey</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td><td align="left" colspan="1" rowspan="1">04/2020-12/2022</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-1273</td><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">Moderna TX, Inc.</td><td align="left" colspan="1" rowspan="1">30,000<break/>Adults</td><td align="left" colspan="1" rowspan="1">2<break/>Day 1 and Day 29</td><td align="left" colspan="1" rowspan="1">100 locations:<break/>USA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link><break/>COVE study</td><td align="left" colspan="1" rowspan="1">07/2020-10/2022</td></tr><tr><td align="left" colspan="1" rowspan="1">Ad5-nCoV (5E10vp)</td><td align="left" colspan="1" rowspan="1">Non-replicating viral vector</td><td align="left" colspan="1" rowspan="1">CanSino Biologics Inc.<break/>NPO Petrovax</td><td align="left" colspan="1" rowspan="1">40,000<break/>Adults<break/>500<break/>18-85 years</td><td align="left" colspan="1" rowspan="1">1<break/>1</td><td align="left" colspan="1" rowspan="1">1 location:<break/>Pakistan<break/>7 locations<break/>Russia</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526990">NCT04526990</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04540419">NCT04540419</ext-link></td><td align="left" colspan="1" rowspan="1">09/2020-01/2022<break/>09/2020-07/2021</td></tr><tr><td align="left" colspan="1" rowspan="1">Gam-COVID-Vac</td><td align="left" colspan="1" rowspan="1">Non-replicating viral vector</td><td align="left" colspan="1" rowspan="1">Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</td><td align="left" colspan="1" rowspan="1">40,000<break/>Adults</td><td align="left" colspan="1" rowspan="1">2<break/>Day 1 and Day 21</td><td align="left" colspan="1" rowspan="1">23 locations:<break/>Russia</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link></td><td align="left" colspan="1" rowspan="1">09/2020-05/2021</td></tr><tr><td align="left" colspan="1" rowspan="1">Ad26.COV2.S</td><td align="left" colspan="1" rowspan="1">Non-replicating viral vector</td><td align="left" colspan="1" rowspan="1">Janssen Vaccines &amp; Prevention B.V.</td><td align="left" colspan="1" rowspan="1">60,000<break/>Adults</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">246 locations:<break/>USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, and South-Africa</td><td align="left" colspan="1" rowspan="1">ENSEMBLE<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link></td><td align="left" colspan="1" rowspan="1">09/2020-03/2023</td></tr><tr><td align="left" colspan="1" rowspan="1">Oxford ChAdOx1-S<break/>(AZD1222)</td><td align="left" colspan="1" rowspan="1">Non-replicating viral vector</td><td align="left" colspan="1" rowspan="1">University of Oxford<break/>AstraZeneca</td><td align="left" colspan="1" rowspan="1">30,000<break/>Adults</td><td align="left" colspan="1" rowspan="1">2<break/>Separated by 4 weeks</td><td align="left" colspan="1" rowspan="1">62 locations:<break/>USA</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link></td><td align="left" colspan="1" rowspan="1">08/2020-10/2022</td></tr><tr><td align="left" colspan="1" rowspan="1">WIBP vaccine<break/>BBIBP-CorV<break/>(Participants receive either WIBP vaccine or BBIBP-CorV)</td><td align="left" colspan="1" rowspan="1">Inactivated (Vero cells)</td><td align="left" colspan="1" rowspan="1">China National Biotec Group Company Limited</td><td align="left" colspan="1" rowspan="1">45,000<break/>Adults</td><td align="left" colspan="1" rowspan="1">2<break/>Day 1 and Day 21</td><td align="left" colspan="1" rowspan="1">6 locations:<break/>Bahrain, Egypt, Jordan, United Arab Emirates</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link></td><td align="left" colspan="1" rowspan="1">07/2020-09/2021</td></tr><tr><td align="left" colspan="1" rowspan="1">BBIBP-CorV</td><td align="left" colspan="1" rowspan="1">Inactivated (Vero cells)</td><td align="left" colspan="1" rowspan="1">Laboratorio Elea Phoenix S.A.</td><td align="left" colspan="1" rowspan="1">3,000<break/>Adults</td><td align="left" colspan="1" rowspan="1">2<break/>Day 1 and Day 21</td><td align="left" colspan="1" rowspan="1">4 locations:<break/>Argentina</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04560881">NCT04560881</ext-link></td><td align="left" colspan="1" rowspan="1">09/2020-12/2021</td></tr><tr><td align="left" colspan="1" rowspan="1">CoronaVac</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Health Institutes of Turkey<break/>Sinovac, Butantan Institute<break/>PT Bio Farma</td><td align="left" colspan="1" rowspan="1">13,000<break/>18&#8211;59 years<break/>8870<break/>Adults<break/>1620<break/>18&#8211;59 years</td><td align="left" colspan="1" rowspan="1">2<break/>Separated by 14 days</td><td align="left" colspan="1" rowspan="1">24 locations:<break/>Turkey<break/>12 locations:<break/>Brazil<break/>1 location:<break/>Indonesia</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04582344">NCT04582344</ext-link><break/>PROFISCOV <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04508075">NCT04508075</ext-link></td><td align="left" colspan="1" rowspan="1">10/2020-04/2021<break/>07/2020-10/2021<break/>08/2020-09/2021</td></tr><tr><td align="left" colspan="1" rowspan="1">Covaxin</td><td align="left" colspan="1" rowspan="1">Inactivated<break/>(Vero cells)</td><td align="left" colspan="1" rowspan="1">Bharat Biotech International limited</td><td align="left" colspan="1" rowspan="1">25,800<break/>Adults</td><td align="left" colspan="1" rowspan="1">2<break/>Separated by 28 days</td><td align="left" colspan="1" rowspan="1">23 locations<break/>India</td><td align="left" colspan="1" rowspan="1">CTRI/2020/11/028976</td><td align="left" colspan="1" rowspan="1">11/2020- 11/2021</td></tr><tr><td align="left" colspan="1" rowspan="1">NVX-CoV2373</td><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Novavax, Inc</td><td align="left" colspan="1" rowspan="1">9,000<break/>18-84 years</td><td align="left" colspan="1" rowspan="1">2<break/>Day 1 and Day 21</td><td align="left" colspan="1" rowspan="1">United Kingdom</td><td align="left" colspan="1" rowspan="1">2020-004123-16</td><td align="left" colspan="1" rowspan="1">09/2020-ongoing</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: BIBP: Beijing Institute of Biological Products Co., Ltd; WIBP: Wuhan Institute of Biological Products Co., Ltd; m/y: month/ year.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec0110"><label>7.1</label><title>Inactivated vaccines</title><p id="par0190">Inactivated vaccines are produced <italic toggle="yes">in vitro</italic> by the inoculation of mammalian cells, usually Vero cells, certified by the WHO for vaccine production, followed by chemical inactivation with &#946;-propiolactone [<xref rid="bib0125" ref-type="bibr">25</xref>]. Currently, 15 inactivated vaccines are assessed in various clinical trial phases, among them the BBIBP-CorV, CoronaVac, WIBP vaccine, and Covaxin have entered phase III (<xref rid="tbl0005" ref-type="table">Table 1</xref>) (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape" id="intr0020">https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape</ext-link>). None of these phase III clinical trials assessing inactivated vaccines has provided a preliminary report of their efficacy.</p><p id="par0195">BBIBP-CorV, with aluminum hydroxide as an adjuvant, was found to be safe and induced immune response on day 42 in vaccinated adults below and over 60 years old in a randomized placebo-controlled, double-blind phase I/II clinical trial [<xref rid="bib0670" ref-type="bibr">134</xref>]. The neutralizing antibody titer (&#8764;256) was higher with a 4-&#956;g dose and an immunization scheduled on days 1 and 21 [<xref rid="bib0670" ref-type="bibr">134</xref>]. BBIBP-CorV was approved for limited use in the United Arab Emirates in September 2020.</p><p id="par0200">In phase II clinical trial, CoronaVac vaccine (3 &#956;g) with aluminum hydroxide as an adjuvant was well tolerated, no grade 3 adverse reaction was observed. The vaccine promoted immunogenicity 28 days following a 2-doses scheduled 14 days apart [<xref rid="bib0675" ref-type="bibr">135</xref>]. The neutralizing antibody titers ranged from 23.8&#8211;65.4 when measured 28 days after a 2-doses scheduled; the titer was reduced in the older subjects [<xref rid="bib0675" ref-type="bibr">135</xref>]. The titer was also lower than the average neutralizing antibody titer (163.7) measured in convalescent patients in the same study [<xref rid="bib0675" ref-type="bibr">135</xref>]. Sinovac received emergency use approval in China to vaccinate high-risk individuals based on the phase II clinical trial. In Brazil, the phase III clinical trial was briefly stopped for 48 h following the death of a participant unrelated to the vaccine injection. The efficacy of CoronaVac should be known before the end of this year.</p><p id="par0205">The WIBP vaccine was assessed in overlapping phases I and II clinical trial. The vaccine was reported to be well-tolerated in an interim report when given a 5-&#956;g dose scheduled 14 days apart; the titer was 121, 14 days after the second injection [<xref rid="bib0680" ref-type="bibr">136</xref>]. WIBP vaccine was approved for limited use in the United Arab Emirates in September 2020.</p><p id="par0210">Covaxin (BBV152) (3 or 6 &#956;g) injected with aluminum hydroxide gel or a TLR7/8 agonist absorbed gel as adjuvant demonstrated good immunogenicity in mice, rats, and rabbits [<xref rid="bib0685" ref-type="bibr">137</xref>]. The injection of Covaxin (3 &#956;g) and TLR7/8 agonist absorbed gel in a 2-doses vaccination scheduled 14 days apart provides immune protection to macaques when challenged by SARS-CoV-2 [<xref rid="bib0690" ref-type="bibr">138</xref>]. In a 4 arms phase I clinical trial (BBV152A, BBV152B, BBV152C, and placebo), adult volunteers not older than 55 years received 2-doses scheduled 14 days apart with differences in antigen concentrations (3 or 6 &#956;g) and 2 adjuvants (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link>). In a contiguous and amended phase II, 380 healthy volunteers between the ages of 12 and 65 received 2-doses 28 days apart (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link>). Bharat Biotech mentioned that the vaccine was well-tolerated, and immunogenicity of BBV152B vas superior to BBV152A, also not statistically significant in a phase I interim report. The phase II clinical trial was subsequently modified as a 2-arms double-blind, randomized trial but not controlled comparing BBV152A and BBV152B (3 &#956;g). The phase III design was based on the phase I interim report and will evaluate the BBV152B candidate vaccine in India across 23 centers. The phase III clinical trial will involve a 2-doses scheduled 28 days apart, recruiting 25,800 volunteers, and starting in November 2020. The immunogenicity will be studied by determining the geometric mean titers by neutralizing antibodies (CTRI/2020/11/028976).</p></sec><sec id="sec0115"><label>7.2</label><title>Live attenuated vaccines</title><p id="par0215">The live attenuated vaccine platform was also used to develop SARS-CoV-2 vaccines. The vaccines developed by Indian Immunologicals Ltd and Griffith University, Mehmet Ali Aydinlar University, and Meissa Vaccines are all in the preclinical phase. COVI-VAC, developed by Codagenix Inc., is entering phase I clinical trial in the United Kingdom (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04619628">NCT04619628</ext-link>). All live attenuated vaccines were generated by codon deoptimization [<xref rid="bib0695" ref-type="bibr">[139]</xref>, <xref rid="bib0700" ref-type="bibr">[140]</xref>, <xref rid="bib0705" ref-type="bibr">[141]</xref>]. The live attenuated vaccines have been developed to treat several diseases, such as tuberculosis, measles, mumps, rubella, varicella, yellow fever, and influenza [<xref rid="bib0710" ref-type="bibr">142</xref>]. The live attenuated vaccines can replicate within the host cells and be given intranasally to provide continuous antigenic stimulation, mucosal, and cell-mediated immune responses [<xref rid="bib0715" ref-type="bibr">143</xref>,<xref rid="bib0720" ref-type="bibr">144</xref>]. The route of administration of the vaccines is critical to induce a humoral and cell-mediated immune response. All the vaccines, currently in phase III clinical trials, are injected intramuscularly, which leads to a strong IgG induction but does not improve the IgA secretion in the upper respiratory tract or the protective mucosal immunity [<xref rid="bib0725" ref-type="bibr">145</xref>]. Thus, intranasal immunization may hold the advantage of protecting the upper respiratory tract, the primary port of entry of SARS-CoV-2. The live attenuated vaccine&#8217;s primary concern is the risk of mutation, which may confer an increased virulence. Also, the occurrence is shallow; the evolution of the attenuated virus needs to be check regularly.</p></sec><sec id="sec0120"><label>7.3</label><title>Protein subunit vaccines</title><p id="par0220">Protein subunit vaccines account for the highest number of vaccines developed (80). The majority is still in preclinical phases, 10 in phase I, 5 in phase I/II, 1 in phase II, and 1, NVX-CoV2373, currently recruiting in the United Kingdom for a phase III clinical trial. The protein subunit vaccine is based on synthetic peptides or recombinant proteins. The spike protein is the most suitable antigen to promote neutralizing antibodies; others use the spike protein&#8217;s RBD domain. These recombinant proteins are produced in various systems, including insect cells (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04522089">NCT04522089</ext-link>), mammalian cells (CHO cells) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04466085">NCT04466085</ext-link>), yeast [<xref rid="bib0730" ref-type="bibr">146</xref>], or plants [<xref rid="bib0735" ref-type="bibr">147</xref>]. NVX-CoV2373 contains the recombinant full-length spike glycoprotein optimized in the established baculovirus Spodoptera frugiperda (Sf9) insect cell-expression system and matrix-M1 adjuvant [<xref rid="bib0740" ref-type="bibr">148</xref>]. The participants received two injections of NVX-CoV2373 at day 0 and day 21 in a randomized placebo control observer-blinded phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>). The vaccine was well-tolerated as no adverse event was reported in all treatment conditions [<xref rid="bib0740" ref-type="bibr">148</xref>]. Two-dose regimens of 5-&#956;g and 25-&#956;g rSARS-CoV-2 spike protein plus matrix-M1 had a similar response, and all participants had seroconversion [<xref rid="bib0740" ref-type="bibr">148</xref>]. The geometric mean fold rise was increased by 5 times with adjuvant matrix-M1 at day 21 (5.2 and 6.3 for doses of 5 and 25 &#956;g, respectively) and by 100 times at day 35 for doses of 5 and 25 &#956;g with adjuvant matrix-M1 (195 and 165, respectively) when compared to the single vaccination without adjuvant [<xref rid="bib0740" ref-type="bibr">148</xref>]. The matrix-M1 also stimulate a T-cell response; overall, the NVX-CoV2373 induced an immune response comparable to the Covid19 patients with significant illness [<xref rid="bib0740" ref-type="bibr">148</xref>]. The preliminary vaccine efficacy data are still pending for the NVX-CoV2373 phase III clinical trial. Novavax made a manufacturing agreement with Serum Institute of India Private Limited to manufacture 2 billion doses per year from 2021, as mentioned in a press release (ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-manufacturing-agreement-serum). The vaccine will only require refrigeration for storage.</p></sec><sec id="sec0125"><label>7.4</label><title>Virus-like particle vaccines</title><p id="par0225">Virus-like particles are non-infectious and non-replicating self-assembled nanostructures exposing key viral proteins. Currently, 16 virus-like particle vaccines are developed, including 1 vaccine in phase I/II (ACTRN12620000817943) sponsored by SpyBiotech and Serum Institute of India in Australia, and 1 vaccine (CoVLP) in phase II/III (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04636697">NCT04636697</ext-link>) sponsored by Medicago Inc in Canada and not yet recruiting. Medicago Inc. has developed a plant-based system using tobacco plants to produce virus-like particles (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medicago.com/en/pipeline/" id="intr0025">https://www.medicago.com/en/pipeline/</ext-link>) [<xref rid="bib0735" ref-type="bibr">147</xref>]. The RBD-HBsAg-VLPs-Covid vaccine is based on the RBD domain of SARS-CoV-2 conjugated to the hepatitis B surface antigen (HBsAg) virus-like particles. The adult volunteers will receive 2 doses, 28 days apart (ACTRN12620000817943).</p></sec><sec id="sec0130"><label>7.5</label><title>Replicating and non-replicating viral vectors vaccines</title><p id="par0230">Replicating and non-replicating viral vectors account for 20 and 37 of the vaccines currently developed, respectively, and both stimulate humoral and cellular immune responses. The replicating vector vaccines infect cells that produce the antigen and more viral vectors that will infect more cells. These replicating vectors are usually derived from attenuated viruses or strains of viruses developed for vaccination and shuttle a gene expressing a viral protein, commonly the viral spike protein. Most of the replicating viral vectors are in the early phase of development. Only 3 of them are entering clinical trials, including DelNS1-2019-nCoV-RBD-OPT1 sponsored by the Jiangsu Provincial Center For Disease Control and Prevention and Beijing WANTAI Biological Pharmacy Enterprise Co, and assessed in a phase I clinical trial (ChiCTR2000037782) for the safety of the intranasal spray delivery of the influenza virus vector platform, carrier of the receptor-binding domain gene which could promote mucosal immunity. Merck Sharp &amp; Dohme Corp is sponsoring two vaccines. The V590 vaccine is based on the recombinant vesicular stomatitis virus (rVSV) platform and shuttles a gene coding for the spike protein in a phase I clinical trial, not yet recruiting (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04569786">NCT04569786</ext-link>) [<xref rid="bib0745" ref-type="bibr">149</xref>,<xref rid="bib0750" ref-type="bibr">150</xref>]. The V591 vaccine uses the attenuated measles vector platform to carry a gene coding for the spike protein and will be evaluated in a phase 1/II currently recruiting (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04498247">NCT04498247</ext-link>) [<xref rid="bib0750" ref-type="bibr">150</xref>].</p><p id="par0235">The non-replicating viral vectors account 4 vaccines currently in phase III clinical trials (<xref rid="tbl0005" ref-type="table">Table 1</xref>). These vectors are mostly based on recombinant human or simian adenovirus vectors. However, they can also use platforms based on the adeno-associated virus, parainfluenza virus, alphavirus, herpesvirus, and poxviruses (NYVAC, vaccinia virus Ankara (MVA), canarypox (ALVAC), or fowlpox (FPV)) [<xref rid="bib0755" ref-type="bibr">[151]</xref>, <xref rid="bib0760" ref-type="bibr">[152]</xref>, <xref rid="bib0765" ref-type="bibr">[153]</xref>]. The recombinant viral vectors are replication-deficient and produced the antigen in infected cells. All non-replicating viral vectors in phase III clinical trials are carriers of a gene coding for the viral spike protein [<xref rid="bib0760" ref-type="bibr">152</xref>,<xref rid="bib0765" ref-type="bibr">153</xref>].</p><p id="par0240">The recombinant adenovirus type-5-vectored COVID-19 vaccine (Ad5-nCoV) produced by CanSino Biological Inc was evaluated in phase II clinical trial and demonstrated to be well tolerated with only mild and transients adverse effects such as fever and induced a rapid immune response. The neutralizing antibody responses to live SARS-CoV-2 had a geometric mean titer of 19.5 and 18.3 in participants receiving 1 &#215; 10&#185;&#185; and 5 &#215; 10&#185;&#8304; viral particles, respectively, at day 28 post-vaccination [<xref rid="bib0770" ref-type="bibr">154</xref>]. These results prompted the Chinese military to bypass phase III and restricted its approval to military personnel. Ad5-nCoV is concurrently assessed in phase III in Pakistan and Russia, phase II in China (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04341389">NCT04341389</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566770">NCT04566770</ext-link>), phase I/II in Canada (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04398147">NCT04398147</ext-link>), and phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04313127">NCT04313127</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04568811">NCT04568811</ext-link>) in China.</p><p id="par0245">The Gam-COVID-Vac developed by the Gamaleya Research Institute is based on two recombinant adenovirus vectors rAd5 and rAd26, encoding both for the viral spike protein [<xref rid="bib0760" ref-type="bibr">152</xref>]. Adult volunteers received either of the recombinant adenoviruses in a phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436471">NCT04436471</ext-link>) and were assessed over 28 days following a single injection, while in phase II, rAd26 was given on day 0, and rAd5 on day 21 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04437875">NCT04437875</ext-link>) [<xref rid="bib0760" ref-type="bibr">152</xref>]. The neutralizing antibodies were only present when both vectors were injected, and the neutralizing antibody responses to live SARS-CoV-2 had a geometric mean titer of &#8764;49 in participants receiving 1 &#215; 10&#185;&#185; of both viral particles, 21 days post-vaccination [<xref rid="bib0760" ref-type="bibr">152</xref>]. The Russian Ministry of Health decided to forgo the phase III clinical trial before licensing the Gam-COVID-Vac under the trade name Sputnik V, as a reminder of the space race that took place more than 60 years ago. Sputnik V is currently evaluated in Russia in a phase III clinical trial with an enrollment target of 40,000 participants (<xref rid="tbl0005" ref-type="table">Table 1</xref>); more than 20,000 participants already received the first dose, and over 16,000 participants received both. The first interim report analysis of the Sputnik V vaccine efficacy against SARS-CoV-2, obtained 21 days after the first injection, was reported to be 92 % based on 20 confirmed cases split between the vaccinated and placebo groups (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sputnikvaccine.com/newsroom/pressreleases/" id="intr0030">https://sputnikvaccine.com/newsroom/pressreleases/</ext-link>). The ongoing phase III clinical is not reporting unexpected adverse effects. The Sputnik V is produced as a lyophilized formulation requiring refrigeration or frozen formulation (maximum &#8722;18 &#176;C). The Russian Direct Investment Fund organizing the vaccine&#8217;s manufacture plans 500 million doses per year in multiple countries.</p><p id="par0250">Janssen Pharmaceutica produces another vaccine based on the recombinant adenovirus (Ad26) currently in phase III clinical trial named ENSEMBLE (<xref rid="tbl0005" ref-type="table">Table 1</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.jnj.com/media-center" id="intr0035">https://www.jnj.com/media-center</ext-link>). The Ad26.COV2.S vaccine was evaluated in phase I/II clinical trial and demonstrated to be safe after a single injection of either 5 &#215; 10<sup>10</sup> or 1 &#215; 10<sup>11</sup> viral particles. The SARS-CoV-2 serum neutralizing antibody titers, measured on day 29, was not provided [<xref rid="bib0775" ref-type="bibr">155</xref>]. The preliminary vaccine efficacy data are still pending. Jansen Pharmaceutica plans to manufacture 1 billion doses per year from 2021 and will only require refrigeration for storage.</p><p id="par0255">The last non-replicating vector vaccine in phase III clinical trial, sponsored by the University of Oxford and AstraZeneca, is the ChAdOx1 nCoV-19 vaccine (AZD1222) based on the chimpanzee replication-deficient adenovirus vector (<xref rid="tbl0005" ref-type="table">Table 1</xref>). The SARS-CoV-2 spike gene was inserted into the E1 locus of the ChAdOx1 adenovirus genome. The use of animal adenovirus may decrease the preexisting vector immunity observed using a human viral vector [<xref rid="bib0770" ref-type="bibr">154</xref>]. The safety of the ChAdOx1 nCoV-19 was assessed in phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>). The vaccine was administrated as a single dose and appeared safe and well-tolerated [<xref rid="bib0780" ref-type="bibr">156</xref>]. The Marburg VN assay measured the neutralizing antibody responses to live SARS-CoV-2; 62 % of recipients (23 out of 37) had a median titer of 29 (24&#8211;32) 56 days after a single of 5 &#215; 10<sup>10</sup> viral particles [<xref rid="bib0780" ref-type="bibr">156</xref>]. The preliminary vaccine efficacy data for the phase III clinical trial are still pending. The phase III clinical trial was interrupted in the USA in September for 50 days after a patient developed symptoms consistent with transverse myelitis and restarted after reviewing the safety data. AstraZeneca plans to supply 400 million doses at no profit by the end of 2020 under Europe&#8217;s Inclusive Vaccines Alliance (IVA) to all European Union member states. Similar agreements with the UK, USA, the Coalition for Epidemic Preparedness Innovations, and Gavi the Vaccine Alliance were made to manufacture 700 million doses. A license agreement was also completed with the Serum Institute of India to supply a billion doses for low- and middle-income countries. The vaccine will only require refrigeration for storage, facilitating its distribution worldwide.</p></sec><sec id="sec0135"><label>7.6</label><title>RNA vaccines</title><p id="par0260">RNA vaccines are a recent addition to the vaccine armory. The discovery that the intramuscular injection of RNA or DNA led to the expression of encoded proteins and elicited B and T cell immune response paved the way for the emergence of nucleic acid vaccines [<xref rid="bib0785" ref-type="bibr">157</xref>,<xref rid="bib0790" ref-type="bibr">158</xref>]. Two types of RNA vaccine platforms are available, either conventional mRNA or self-amplifying mRNA [<xref rid="bib0795" ref-type="bibr">159</xref>]. The conventional mRNA is based on a simple open-reading frame flanked by untranslated regions (UTRs), a 5&#8217; cap, and a 3&#8217; poly(A) tail. The self-amplifying mRNA is based on a positive-sense single-stranded RNA virus, commonly alphaviruses. The modified viral genome comprises a gene of interest, inserted at the place of the sequences coding for structural proteins, the viral nonstructural proteins coding sequence essential for the RNA amplification, UTRs, a cap, and a poly(A) tail [<xref rid="bib0795" ref-type="bibr">159</xref>]. The modification of the mRNA increases its stability, its encapsulation into lipid nanoparticles improves the cellular delivery; the cytoplasmic localization of the translation and non-integration into the host genome are other advantages of the mRNA vaccine. Currently, 33 mRNA vaccines are developed, including 26 in the preclinical phase, 2 in phases I and I/II, 1 in phase II, and 2 in phase III, namely BNT162b2 sponsored by BioNTech SE and Pfizer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>) and mRNA-1273 sponsored by Moderna TX and National Institute of Allergy and Infectious Diseases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>) (<xref rid="tbl0005" ref-type="table">Table 1</xref>). BioNTech SE and Pfizer assessed two vaccines, BNT162b1 and BNT162B2 vaccines, in a multi-phase I, II, and III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>). BNT162b1 contains the mRNA encoding for the spike protein&#8217;s receptor-binding domain fused to a T4 fibritin-derived &#8216;foldon&#8217; trimerization domain to increase its immunogenicity [<xref rid="bib0800" ref-type="bibr">160</xref>], while BNT162b2 contains the mRNA coding for the full-length spike protein [<xref rid="bib0805" ref-type="bibr">161</xref>]. The mRNA was optimized to improve its stability and processivity by incorporating 1-methylpseudouridine instead of uridine and encapsulated into lipid nanoparticles to decrease its immunogenicity [<xref rid="bib0800" ref-type="bibr">160</xref>]. BNT162b1 was assessed, the phase I determined the vaccine candidate and the dose [<xref rid="bib0810" ref-type="bibr">162</xref>]. In an intermediate report of the placebo-controlled, observer-blinded phase I/II, BNT162b1vaccine induced CD4<sup>+</sup>, and CD8<sup>+</sup> T-cell responses in almost all participants, with TH1 helper response [<xref rid="bib0800" ref-type="bibr">160</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>). Adults participants (18&#8211;55 years) received two doses of 1 and 50 &#956;g of BNT162b1, 21 days apart; the geometric mean titers of SARS-CoV-2 serum neutralizing antibodies on day 43 were 0.7-fold to 3.5-fold of those of the recovered individuals for the 1 and 50 &#956;g dose, respectively [<xref rid="bib0800" ref-type="bibr">160</xref>]. The BNT162b2 vaccine demonstrated similar SARS-CoV-2 neutralizing geometric mean titers as BNT162b1 but demonstrated less systemic adverse effects, particularly in elderly adults 65&#8211;85 years) [<xref rid="bib0805" ref-type="bibr">161</xref>]. Recently, Pfizer and BioNTech announced that the phase III clinical trial for the BNT162b2 vaccine reached all the primary efficacy endpoints. The phase III clinical trial recruited over 43,000 volunteers, of whom 41,135 have received a second dose of the vaccine candidate as of November 13, 2020, reported no serious adverse effects; only fatigue and headache were reported in 3.8 and 2% of the participants, respectively. In a press release (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.businesswire.com/news/home/20201118005595/en/" id="intr0040">www.businesswire.com/news/home/20201118005595/en/</ext-link>), Pfizer and BioNTech announced that the BNT162b2 vaccine demonstrated 95 % efficacy and more than 94 % in adults over 65 beginning 28 days after the first dose based on the analysis of 170 confirmed cases of Covid-19, including 162 in the placebo group (9 severe cases) and 8 in the vaccine group (1 severe case). The vaccine was efficacious across age, gender, and ethnicities. Pfizer and BioNTech initiated a rolling submission to the European Medicines Agency (EMA) in late October and applied on November 20, 2020, for an emergency use authorization to the FDA, which could permit a limited use by the following month. This is the first SARS-CoV-2 vaccine to seek FDA approval in the US. The vaccine needs to be stored at low temperature (-60 to &#8722;80 &#176;C), which may limit its diffusion in remote areas. Pfizer and BioNTech reported the production of 50 million doses in 2020 and will scale up to 1.3 billion doses in 2021.</p><p id="par0265">The Moderna vaccine, mRNA-1273, which encodes the spike protein stabilized in the prefusion form [<xref rid="bib0815" ref-type="bibr">163</xref>], demonstrated to be safe in phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>). The participants received either 25, 100, or 250 &#956;g scheduled 28 days apart; the 250-&#956;g dose reported the most severe adverse events [<xref rid="bib0820" ref-type="bibr">164</xref>]. The median magnitude of antibody responses after the first vaccination was similar to convalescent serum samples [<xref rid="bib0820" ref-type="bibr">164</xref>]. A later study supported using the 100 &#956;g for a phase III clinical trial [<xref rid="bib0825" ref-type="bibr">165</xref>]. The vaccine is developed in collaboration with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. Moderna announced on November 16, 2020, that the mRNA-1273 met all the primary efficacy endpoint (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.modernatx.com/news-releases" id="intr0045">https://investors.modernatx.com/news-releases</ext-link>). The phase III recruited more than 30,000 volunteers and demonstrated safety and efficacy across all ages, gender, and ethnicities. Fatigue, myalgia, arthralgia, headache, and pain were observed in 9.7, 8.9, 5.2, 4.5, and 4.1 % of the participants, respectively, following the second injection and were all short-lived. The first interim analysis established the efficacy of the vaccine at 94.5 %, based on the analysis of 95 cases, of which 90 cases, including 11 severe cases, were in the placebo group and 5 in the vaccine group with no severe case observed. Moderna initiated a rolling submission to the European Medicines Agency (EMA) on November 17, 2020, and will apply for emergency use authorization to the FDA in the next few weeks. The mRNA-1273 vaccine will be easier to store and distribute worldwide than the BNT162b2 vaccine; the vaccine can be kept refrigerated for 30 days or frozen (-15 to &#8722;25 &#176;C) for long term storage. Moderna plans to manufacture 500 million to 1 billion doses in 2021 and coordinate its distribution with U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed, and McKesson.</p></sec><sec id="sec0140"><label>7.7</label><title>DNA vaccines</title><p id="par0270">The DNA vaccines are based on plasmids that can be amplified at a large scale in bacteria and expressed in eukaryotic cells. DNA vaccines have been approved for veterinary use (for review, see [<xref rid="bib0830" ref-type="bibr">166</xref>]). For human applicability, concerns have been raised on the risk of integration of DNA plasmid vaccine into the host genome or conferring to the microbiota antibiotic resistance genes. The opportunity for the integration to occur is less frequent than the occurrence of random genetic mutations [<xref rid="bib0835" ref-type="bibr">167</xref>]. In subsequent studies, no integration was detected in the genome host or antibiotic resistance acquisition by the microbiome [<xref rid="bib0830" ref-type="bibr">166</xref>]. DNA vaccines often show low immunogenicity, restricted to the injection site as delivery depends on electroporation, or a gene gun using pressurized helium to force the plasmid inside the cells [<xref rid="bib0840" ref-type="bibr">168</xref>]. The DNA vaccine plasmids for SARS-CoV-2 encode for the spike protein [<xref rid="bib0845" ref-type="bibr">169</xref>]. Currently, 22 DNA vaccines are developed; 5 are or will be evaluated in phase I/II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445389">NCT04445389</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04447781">NCT04447781</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04463472">NCT04463472</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527081">NCT04527081</ext-link>, and CTRI/2020/07/026352) and 2 in phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04591184">NCT04591184</ext-link>).</p></sec></sec><sec id="sec0145"><label>8</label><title>Conclusion</title><p id="par0275">The volume of research undertaken worldwide and its rapid transition from the bench to the clinic have demonstrated a level of urgency and collaboration never witnessed before to address individual irresponsibility and outmoded politicians. No therapeutic strategy has yet been proven to be determinant for the treatment of SARS-CoV-2. However, eleven vaccines are being evaluated in phase III clinical trials. The preliminary data demonstrated seroconversion and the presence of neutralizing antibodies to various degrees, depending on the vaccine. Three vaccines, Sputnik V, BNT162b2, and mRNA-1273, have demonstrated efficacy superior to 90 %, including in high-risk subgroups. These vaccines will be licensed soon worldwide, but enormous challenges will remain to produce sufficient doses of the vaccines and distribute them worldwide, especially in low to middle-income countries.</p></sec><sec id="sec0150"><title>Funding</title><p id="par0280">This manuscript was not funded.</p></sec><sec id="sec0155"><title>Authors' contributions</title><p id="par0285">Moiz Bakhiet generated the idea of the review and wrote part of the manuscript. Sebastien Taurin wrote part of the manuscript and made the figures.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0290">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="book" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>World Health</surname><given-names>O.</given-names></name></person-group><part-title>Coronavirus Disease (COVID-19): Weekly Epidemiological, Update 1</part-title><year>2020</year><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Munster</surname><given-names>V.J.</given-names></name><etal/></person-group><article-title>A novel coronavirus emerging in China&#8212;key questions for impact assessment</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>8</issue><year>2020</year><fpage>692</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">31978293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2000929</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="book" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>T.S.</given-names></name></person-group><part-title>Human Coronavirus-229E, -OC43, -NL63, and -HKU1</part-title><source>Reference Module in Life Sciences</source><year>2020</year><comment>p. B978-0-12-809633-8.21501-X</comment></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Azhar</surname><given-names>E.I.</given-names></name><etal/></person-group><article-title>Evidence for camel-to-human transmission of MERS coronavirus</article-title><source>N. Engl. J. Med.</source><volume>370</volume><issue>26</issue><year>2014</year><fpage>2499</fpage><lpage>2505</lpage><pub-id pub-id-type="pmid">24896817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1401505</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</article-title><source>Science</source><volume>302</volume><issue>5643</issue><year>2003</year><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1087139</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.-Z.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.C.</given-names></name></person-group><article-title>A genomic perspective on the origin and emergence of SARS-CoV-2</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">32220310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.03.035</pub-id><pub-id pub-id-type="pmcid">PMC7194821</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K.G.</given-names></name><etal/></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat. Med.</source><volume>26</volume><issue>4</issue><year>2020</year><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Orhan</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Senol Deniz</surname><given-names>F.S.</given-names></name></person-group><article-title>Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS-CoV-2?</article-title><source>Nat. Prod. Bioprospect.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13659-020-00250-4</pub-id><pub-id pub-id-type="pmcid">PMC7289229</pub-id><pub-id pub-id-type="pmid">32529545</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><issue>10224</issue><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China</article-title><source>Cell Host Microbe</source><volume>27</volume><issue>3</issue><year>2020</year><fpage>325</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">32035028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2020.02.001</pub-id><pub-id pub-id-type="pmcid">PMC7154514</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>271</fpage><lpage>280</lpage><comment>e8</comment><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.K.</given-names></name><etal/></person-group><article-title>The SARS coronavirus nucleocapsid protein--forms and functions</article-title><source>Antiviral Res.</source><volume>103</volume><year>2014</year><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">24418573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2013.12.009</pub-id><pub-id pub-id-type="pmcid">PMC7113676</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title><source>Science</source><year>2020</year><comment>p. eabb9983</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmcid">PMC7199903</pub-id><pub-id pub-id-type="pmid">32366695</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="book" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Mercatelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>F.M.</given-names></name></person-group><part-title>Geographic and Genomic Distribution of SARS-CoV-2 Mutations</part-title><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2020.01800</pub-id><pub-id pub-id-type="pmcid">PMC7387429</pub-id><pub-id pub-id-type="pmid">32793182</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Increasing host cellular receptor-angiotensin-Converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection</article-title><source>J. Med. Virol.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26139</pub-id><pub-id pub-id-type="pmcid">PMC7300907</pub-id><pub-id pub-id-type="pmid">32497323</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><issue>6965</issue><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02145</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>102</volume><issue>22</issue><year>2005</year><fpage>7988</fpage><lpage>7993</lpage><pub-id pub-id-type="pmid">15897467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0409465102</pub-id><pub-id pub-id-type="pmcid">PMC1142358</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Bestle</surname><given-names>D.</given-names></name><etal/></person-group><article-title>TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets</article-title><source>bioRxiv</source><year>2020</year><comment>p. 2020.04.15.042085</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.26508/lsa.202000786</pub-id><pub-id pub-id-type="pmcid">PMC7383062</pub-id><pub-id pub-id-type="pmid">32703818</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>281</fpage><lpage>292</lpage><comment>e6</comment><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title><source>Proc. Natl. Acad. Sci.</source><volume>117</volume><issue>13</issue><year>2020</year><fpage>7001</fpage><lpage>7003</lpage><pub-id pub-id-type="pmid">32165541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2002589117</pub-id><pub-id pub-id-type="pmcid">PMC7132130</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name name-style="western"><surname>Gierer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies</article-title><source>J. Virol.</source><volume>87</volume><issue>10</issue><year>2013</year><fpage>5502</fpage><lpage>5511</lpage><pub-id pub-id-type="pmid">23468491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00128-13</pub-id><pub-id pub-id-type="pmcid">PMC3648152</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name name-style="western"><surname>Shirato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawase</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</article-title><source>J. Virol.</source><volume>87</volume><issue>23</issue><year>2013</year><fpage>12552</fpage><lpage>12561</lpage><pub-id pub-id-type="pmid">24027332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01890-13</pub-id><pub-id pub-id-type="pmcid">PMC3838146</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name name-style="western"><surname>Shulla</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry</article-title><source>J. Virol.</source><volume>85</volume><issue>2</issue><year>2011</year><fpage>873</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">21068237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02062-10</pub-id><pub-id pub-id-type="pmcid">PMC3020023</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 invades host cells via a novel route: CD147-spike protein</article-title><source>bioRxiv</source><year>2020</year><comment>p. 2020.03.14.988345</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00426-x</pub-id><pub-id pub-id-type="pmcid">PMC7714896</pub-id><pub-id pub-id-type="pmid">33277466</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name name-style="western"><surname>Ulrich</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pillat</surname><given-names>M.M.</given-names></name></person-group><article-title>CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement</article-title><source>Stem Cell Rev. Rep.</source><volume>16</volume><issue>3</issue><year>2020</year><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">32307653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12015-020-09976-7</pub-id><pub-id pub-id-type="pmcid">PMC7167302</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name name-style="western"><surname>Iacono</surname><given-names>K.T.</given-names></name><etal/></person-group><article-title>CD147 immunoglobulin superfamily receptor function and role in pathology</article-title><source>Exp. Mol. Pathol.</source><volume>83</volume><issue>3</issue><year>2007</year><fpage>283</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">17945211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexmp.2007.08.014</pub-id><pub-id pub-id-type="pmcid">PMC2211739</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name name-style="western"><surname>Crosnier</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum</article-title><source>Nature</source><volume>480</volume><issue>7378</issue><year>2011</year><fpage>534</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">22080952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10606</pub-id><pub-id pub-id-type="pmcid">PMC3245779</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name name-style="western"><surname>Pushkarsky</surname><given-names>T.</given-names></name><etal/></person-group><article-title>CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A</article-title><source>Proc. Natl. Acad. Sci.</source><volume>98</volume><issue>11</issue><year>2001</year><fpage>6360</fpage><lpage>6365</lpage><pub-id pub-id-type="pmid">11353871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.111583198</pub-id><pub-id pub-id-type="pmcid">PMC33473</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells</article-title><source>J. Virol.</source><volume>84</volume><issue>9</issue><year>2010</year><fpage>4183</fpage><lpage>4193</lpage><pub-id pub-id-type="pmid">20147391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02168-09</pub-id><pub-id pub-id-type="pmcid">PMC2863760</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><comment>p. 1620-1620</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmcid">PMC7100515</pub-id><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name name-style="western"><surname>Brierley</surname><given-names>I.</given-names></name><name name-style="western"><surname>Digard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Inglis</surname><given-names>S.C.</given-names></name></person-group><article-title>Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot</article-title><source>Cell</source><volume>57</volume><issue>4</issue><year>1989</year><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">2720781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(89)90124-4</pub-id><pub-id pub-id-type="pmcid">PMC7133225</pub-id></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#945;-ketoamide inhibitors</article-title><source>Science</source><volume>368</volume><issue>6489</issue><year>2020</year><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">32198291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb3405</pub-id><pub-id pub-id-type="pmcid">PMC7164518</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name name-style="western"><surname>Krichel</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Processing of the SARS-CoV pp1a/ab nsp7-10 region</article-title><source>Biochem. J.</source><volume>477</volume><issue>5</issue><year>2020</year><fpage>1009</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">32083638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BCJ20200029</pub-id><pub-id pub-id-type="pmcid">PMC7078746</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name name-style="western"><surname>Knoops</surname><given-names>K.</given-names></name><etal/></person-group><article-title>SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum</article-title><source>PLoS Biol.</source><volume>6</volume><issue>9</issue><year>2008</year><fpage>e226</fpage><pub-id pub-id-type="pmid">18798692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.0060226</pub-id><pub-id pub-id-type="pmcid">PMC2535663</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Methods Mol. Biol.</source><volume>1282</volume><year>2015</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">25720466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmcid">PMC4369385</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>18</issue><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">32109013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><issue>4</issue><year>2020</year><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">32105637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30086-4</pub-id><pub-id pub-id-type="pmcid">PMC7159053</pub-id></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">32007143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmcid">PMC7135076</pub-id></element-citation></ref><ref id="bib0205"><label>41</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name name-style="western"><surname>Rowley</surname><given-names>A.H.</given-names></name></person-group><article-title>Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">32546853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0367-5</pub-id><pub-id pub-id-type="pmcid">PMC7296515</pub-id></element-citation></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>D.</given-names></name></person-group><article-title>Enteric involvement of coronaviruses: is faecal&#8211;oral transmission of SARS-CoV-2 possible?</article-title><source>Lancet Gastroenterol. Hepatol.</source><volume>5</volume><issue>4</issue><year>2020</year><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">32087098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(20)30048-0</pub-id><pub-id pub-id-type="pmcid">PMC7130008</pub-id></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name name-style="western"><surname>Pung</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30528-6</pub-id><pub-id pub-id-type="pmcid">PMC7269710</pub-id><pub-id pub-id-type="pmid">32192580</pub-id></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name name-style="western"><surname>Lauer</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</article-title><source>Ann. Intern. Med.</source><volume>172</volume><issue>9</issue><year>2020</year><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">32150748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-0504</pub-id><pub-id pub-id-type="pmcid">PMC7081172</pub-id></element-citation></ref><ref id="bib0225"><label>45</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>C.-C.</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges</article-title><source>Int. J. Antimicrob. Agents</source><volume>55</volume><issue>3</issue><year>2020</year><fpage>105924</fpage><pub-id pub-id-type="pmid">32081636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.105924</pub-id><pub-id pub-id-type="pmcid">PMC7127800</pub-id></element-citation></ref><ref id="bib0230"><label>46</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>L.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>12</issue><year>2020</year><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">32074444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2001737</pub-id><pub-id pub-id-type="pmcid">PMC7121626</pub-id></element-citation></ref><ref id="bib0235"><label>47</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title><source>Nat. Med.</source><volume>26</volume><issue>5</issue><year>2020</year><fpage>672</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">32296168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0869-5</pub-id></element-citation></ref><ref id="bib0240"><label>48</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name name-style="western"><surname>To</surname><given-names>K.K.-W.</given-names></name><etal/></person-group><article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><issue>5</issue><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32213337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30196-1</pub-id><pub-id pub-id-type="pmcid">PMC7158907</pub-id></element-citation></ref><ref id="bib0245"><label>49</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name name-style="western"><surname>Peiris</surname><given-names>J.S.M.</given-names></name><etal/></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title><source>Lancet</source><volume>361</volume><issue>9371</issue><year>2003</year><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">12781535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(03)13412-5</pub-id><pub-id pub-id-type="pmcid">PMC7112410</pub-id></element-citation></ref><ref id="bib0250"><label>50</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Association between age and clinical characteristics and outcomes of COVID-19</article-title><source>Eur. Respir. J.</source><volume>55</volume><issue>5</issue><year>2020</year><fpage>2001112</fpage><pub-id pub-id-type="pmid">32312864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.01112-2020</pub-id><pub-id pub-id-type="pmcid">PMC7173682</pub-id></element-citation></ref><ref id="bib0255"><label>51</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study</article-title><source>Lancet Microbe</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(20)30004-5</pub-id><pub-id pub-id-type="pmcid">PMC7173822</pub-id><pub-id pub-id-type="pmid">32835326</pub-id></element-citation></ref><ref id="bib0260"><label>52</label><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name name-style="western"><surname>Dobbs</surname><given-names>L.G.</given-names></name></person-group><article-title>Pulmonary surfactant</article-title><source>Annu. Rev. Med.</source><volume>40</volume><issue>1</issue><year>1989</year><fpage>431</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">2658759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.me.40.020189.002243</pub-id></element-citation></ref><ref id="bib0265"><label>53</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title><source>Front. Med.</source><volume>14</volume><issue>2</issue><year>2020</year><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">32170560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11684-020-0754-0</pub-id><pub-id pub-id-type="pmcid">PMC7088738</pub-id></element-citation></ref><ref id="bib0270"><label>54</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name name-style="western"><surname>Monteil</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.04.004</pub-id><pub-id pub-id-type="pmcid">PMC7181998</pub-id><pub-id pub-id-type="pmid">32333836</pub-id></element-citation></ref><ref id="bib0275"><label>55</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name name-style="western"><surname>Sungnak</surname><given-names>W.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nat. Med.</source><volume>26</volume><issue>5</issue><year>2020</year><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">32327758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0868-6</pub-id><pub-id pub-id-type="pmcid">PMC8637938</pub-id></element-citation></ref><ref id="bib0280"><label>56</label><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name name-style="western"><surname>Broz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V.M.</given-names></name></person-group><article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title><source>Nat. Rev. Immunol.</source><volume>16</volume><issue>7</issue><year>2016</year><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">27291964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2016.58</pub-id></element-citation></ref><ref id="bib0285"><label>57</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>J.K.Y.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Inflammasomes and Pyroptosis as therapeutic targets for COVID-19</article-title><source>J. Immunol.</source><year>2020</year><fpage>ji2000513</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2000513</pub-id><pub-id pub-id-type="pmcid">PMC7343621</pub-id><pub-id pub-id-type="pmid">32493814</pub-id></element-citation></ref><ref id="bib0290"><label>58</label><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical and pathological investigation of patients with severe COVID-19</article-title><source>JCI Insight</source><volume>5</volume><issue>12</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.138070</pub-id><pub-id pub-id-type="pmcid">PMC7406259</pub-id><pub-id pub-id-type="pmid">32427582</pub-id></element-citation></ref><ref id="bib0295"><label>59</label><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name name-style="western"><surname>Yoshikawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells</article-title><source>J. Virol.</source><volume>83</volume><issue>7</issue><year>2009</year><fpage>3039</fpage><lpage>3048</lpage><pub-id pub-id-type="pmid">19004938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01792-08</pub-id><pub-id pub-id-type="pmcid">PMC2655569</pub-id></element-citation></ref><ref id="bib0300"><label>60</label><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name name-style="western"><surname>Fujimoto</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Virus clearance through apoptosis-dependent phagocytosis of influenza A virus-infected cells by macrophages</article-title><source>J. Virol.</source><volume>74</volume><issue>7</issue><year>2000</year><fpage>3399</fpage><lpage>3403</lpage><pub-id pub-id-type="pmid">10708457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.74.7.3399-3403.2000</pub-id><pub-id pub-id-type="pmcid">PMC111841</pub-id></element-citation></ref><ref id="bib0305"><label>61</label><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name name-style="western"><surname>Kubelkova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Macela</surname><given-names>A.</given-names></name></person-group><article-title>Innate immune recognition: an issue more complex than expected</article-title><source>Front. Cell. Infect. Microbiol.</source><volume>9</volume><year>2019</year><fpage>241</fpage><pub-id pub-id-type="pmid">31334134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2019.00241</pub-id><pub-id pub-id-type="pmcid">PMC6616152</pub-id></element-citation></ref><ref id="bib0310"><label>62</label><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name name-style="western"><surname>Keidar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients</article-title><source>Circ. Res.</source><volume>97</volume><issue>9</issue><year>2005</year><fpage>946</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">16179584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.RES.0000187500.24964.7A</pub-id></element-citation></ref><ref id="bib0315"><label>63</label><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells</article-title><source>Mol. Immunol.</source><volume>46</volume><issue>3</issue><year>2009</year><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">19041135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2008.10.022</pub-id></element-citation></ref><ref id="bib0320"><label>64</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name name-style="western"><surname>Jeffers</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>101</volume><issue>44</issue><year>2004</year><fpage>15748</fpage><lpage>15753</lpage><pub-id pub-id-type="pmid">15496474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0403812101</pub-id><pub-id pub-id-type="pmcid">PMC524836</pub-id></element-citation></ref><ref id="bib0325"><label>65</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name name-style="western"><surname>Marzi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><volume>78</volume><issue>21</issue><year>2004</year><fpage>12090</fpage><lpage>12095</lpage><pub-id pub-id-type="pmid">15479853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.21.12090-12095.2004</pub-id><pub-id pub-id-type="pmcid">PMC523257</pub-id></element-citation></ref><ref id="bib0330"><label>66</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN</article-title><source>J. Virol.</source><volume>78</volume><issue>11</issue><year>2004</year><fpage>5642</fpage><lpage>5650</lpage><pub-id pub-id-type="pmid">15140961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.11.5642-5650.2004</pub-id><pub-id pub-id-type="pmcid">PMC415834</pub-id></element-citation></ref><ref id="bib0335"><label>67</label><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients</article-title><source>Sci. Rev.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nsr/nwaa041</pub-id><pub-id pub-id-type="pmcid">PMC7108005</pub-id><pub-id pub-id-type="pmid">34676125</pub-id></element-citation></ref><ref id="bib0340"><label>68</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa248</pub-id><pub-id pub-id-type="pmcid">PMC7108125</pub-id><pub-id pub-id-type="pmid">32161940</pub-id></element-citation></ref><ref id="bib0345"><label>69</label><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name name-style="western"><surname>Tufan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Avanoglu Guler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matucci-Cerinic</surname><given-names>M.</given-names></name></person-group><article-title>COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs</article-title><source>Turk. J. Med. Sci.</source><volume>50</volume><issue>SI-1</issue><year>2020</year><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">32299202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3906/sag-2004-168</pub-id><pub-id pub-id-type="pmcid">PMC7195984</pub-id></element-citation></ref><ref id="bib0350"><label>70</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome</article-title><source>Sci. Immunol.</source><volume>5</volume><issue>48</issue><year>2020</year><fpage>eabd2071</fpage><pub-id pub-id-type="pmid">32591408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abd2071</pub-id><pub-id pub-id-type="pmcid">PMC7319493</pub-id></element-citation></ref><ref id="bib0355"><label>71</label><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals</article-title><source>Immunity</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.04.023</pub-id><pub-id pub-id-type="pmcid">PMC7196424</pub-id><pub-id pub-id-type="pmid">32413330</pub-id></element-citation></ref><ref id="bib0360"><label>72</label><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="bib0365"><label>73</label><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name name-style="western"><surname>Gabrielli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>COVID-19 and thrombotic complications: pulmonary thrombosis rather than embolism?</article-title><source>Thromb. Res.</source><volume>193</volume><year>2020</year><fpage>98</fpage><pub-id pub-id-type="pmid">32534328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.thromres.2020.06.014</pub-id><pub-id pub-id-type="pmcid">PMC7278638</pub-id></element-citation></ref><ref id="bib0370"><label>74</label><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name name-style="western"><surname>Zaid</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19</article-title><source>medRxiv</source><year>2020</year><comment>p. 2020.06.23.20137596</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.120.317703</pub-id><pub-id pub-id-type="pmcid">PMC7641188</pub-id><pub-id pub-id-type="pmid">32938299</pub-id></element-citation></ref><ref id="bib0375"><label>75</label><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name name-style="western"><surname>Bautista-Vargas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonilla-Abadia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Canas</surname><given-names>C.A.</given-names></name></person-group><article-title>Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19</article-title><source>J. Thromb. Thrombolysis</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11239-020-02172-x</pub-id><pub-id pub-id-type="pmcid">PMC7282470</pub-id><pub-id pub-id-type="pmid">32519164</pub-id></element-citation></ref><ref id="bib0380"><label>76</label><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name name-style="western"><surname>Nemerson</surname><given-names>Y.</given-names></name></person-group><article-title>Tissue factor and hemostasis</article-title><source>Blood</source><volume>71</volume><issue>1</issue><year>1988</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3275472</pub-id></element-citation></ref><ref id="bib0385"><label>77</label><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name name-style="western"><surname>Mackman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tilley</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Key</surname><given-names>N.S.</given-names></name></person-group><article-title>Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><volume>27</volume><issue>8</issue><year>2007</year><fpage>1687</fpage><lpage>1693</lpage><pub-id pub-id-type="pmid">17556654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.107.141911</pub-id></element-citation></ref><ref id="bib0390"><label>78</label><element-citation publication-type="journal" id="sbref0390"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Computer-aided assessment of the chemokine receptors CXCR3, CXCR4 and CXCR7 expression in gallbladder carcinoma</article-title><source>J. Cell. Mol. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.15219</pub-id><pub-id pub-id-type="pmcid">PMC7339221</pub-id><pub-id pub-id-type="pmid">32512633</pub-id></element-citation></ref><ref id="bib0395"><label>79</label><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name name-style="western"><surname>Cavezzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troiani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corrao</surname><given-names>S.</given-names></name></person-group><article-title>COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review</article-title><source>Clin. Pract.</source><volume>10</volume><issue>2</issue><year>2020</year><fpage>1271</fpage><pub-id pub-id-type="pmid">32509258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4081/cp.2020.1271</pub-id><pub-id pub-id-type="pmcid">PMC7267810</pub-id></element-citation></ref><ref id="bib0400"><label>80</label><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name name-style="western"><surname>Lumley</surname><given-names>S.F.</given-names></name><etal/></person-group><article-title>Antibodies to SARS-CoV-2 are associated with protection against reinfection</article-title><source>medRxiv</source><year>2020</year><comment>p. 2020.11.18.20234369</comment></element-citation></ref><ref id="bib0405"><label>81</label><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name name-style="western"><surname>Prather</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Schooley</surname><given-names>R.T.</given-names></name></person-group><article-title>Reducing transmission of SARS-CoV-2</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6197</pub-id><pub-id pub-id-type="pmid">32461212</pub-id></element-citation></ref><ref id="bib0410"><label>82</label><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name name-style="western"><surname>Kissler</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title><source>Science</source><volume>368</volume><issue>6493</issue><year>2020</year><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">32291278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb5793</pub-id><pub-id pub-id-type="pmcid">PMC7164482</pub-id></element-citation></ref><ref id="bib0415"><label>83</label><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>19</issue><year>2020</year><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">32187464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmcid">PMC7121492</pub-id></element-citation></ref><ref id="bib0420"><label>84</label><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>A trial of Lopinavir-Ritonavir in Covid-19. Reply</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>21</issue><year>2020</year><fpage>e68</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2008043</pub-id><pub-id pub-id-type="pmid">32369286</pub-id></element-citation></ref><ref id="bib0425"><label>85</label><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name name-style="western"><surname>Gautret</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><fpage>105949</fpage><pub-id pub-id-type="pmid">32205204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.105949</pub-id><pub-id pub-id-type="pmcid">PMC7102549</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11718083"/></element-citation></ref><ref id="bib0430"><label>86</label><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name name-style="western"><surname>Million</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France</article-title><source>Travel Med. Infect. Dis.</source><year>2020</year><fpage>101738</fpage><pub-id pub-id-type="pmid">32387409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tmaid.2020.101738</pub-id><pub-id pub-id-type="pmcid">PMC7199729</pub-id></element-citation></ref><ref id="bib0435"><label>87</label><element-citation publication-type="journal" id="sbref0435"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><issue>10229</issue><year>2020</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">32171076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmcid">PMC7270627</pub-id></element-citation></ref><ref id="bib0440"><label>88</label><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro</article-title><source>Cell Discov.</source><volume>6</volume><issue>1</issue><year>2020</year><fpage>28</fpage><pub-id pub-id-type="pmid">32373347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-0169-8</pub-id><pub-id pub-id-type="pmcid">PMC7195821</pub-id></element-citation></ref><ref id="bib0445"><label>89</label><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name name-style="western"><surname>Vankadari</surname><given-names>N.</given-names></name></person-group><article-title>Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><comment>p. 105998-105998</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.105998</pub-id><pub-id pub-id-type="pmcid">PMC7187825</pub-id><pub-id pub-id-type="pmid">32360231</pub-id></element-citation></ref><ref id="bib0450"><label>90</label><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa272</pub-id><pub-id pub-id-type="pmcid">PMC7184452</pub-id><pub-id pub-id-type="pmid">32176772</pub-id></element-citation></ref><ref id="bib0455"><label>91</label><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Efficacy and safety of Lopinavir/Ritonavir or arbidol in adult patients with Mild/Moderate COVID-19: an exploratory randomized controlled trial</article-title><source>Med</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.medj.2020.04.001</pub-id><pub-id pub-id-type="pmcid">PMC7235585</pub-id><pub-id pub-id-type="pmid">32838353</pub-id></element-citation></ref><ref id="bib0460"><label>92</label><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name name-style="western"><surname>Haschke</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects</article-title><source>Clin. Pharmacokinet.</source><volume>52</volume><issue>9</issue><year>2013</year><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">23681967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-013-0072-7</pub-id></element-citation></ref><ref id="bib0465"><label>93</label><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name name-style="western"><surname>Zoufaly</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Human recombinant soluble ACE2 in severe COVID-19</article-title><source>Lancet Respir. Med.</source><volume>8</volume><issue>11</issue><year>2020</year><fpage>1154</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">33131609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30418-5</pub-id><pub-id pub-id-type="pmcid">PMC7515587</pub-id></element-citation></ref><ref id="bib0470"><label>94</label><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><volume>30</volume><issue>3</issue><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmcid">PMC7054408</pub-id></element-citation></ref><ref id="bib0475"><label>95</label><element-citation publication-type="journal" id="sbref0475"><person-group person-group-type="author"><name name-style="western"><surname>Meyerowitz</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Rethinking the role of hydroxychloroquine in the treatment of COVID-19</article-title><source>FASEB J.</source><volume>34</volume><issue>5</issue><year>2020</year><fpage>6027</fpage><lpage>6037</lpage><pub-id pub-id-type="pmid">32350928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202000919</pub-id><pub-id pub-id-type="pmcid">PMC7267640</pub-id></element-citation></ref><ref id="bib0480"><label>96</label><element-citation publication-type="journal" id="sbref0480"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2023184</pub-id><pub-id pub-id-type="pmcid">PMC7727327</pub-id><pub-id pub-id-type="pmid">33264556</pub-id></element-citation></ref><ref id="bib0485"><label>97</label><element-citation publication-type="journal" id="sbref0485"><person-group person-group-type="author"><name name-style="western"><surname>Choy</surname><given-names>K.-T.</given-names></name><etal/></person-group><article-title>Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro</article-title><source>Antiviral Res.</source><year>2020</year><fpage>104786</fpage><pub-id pub-id-type="pmid">32251767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104786</pub-id><pub-id pub-id-type="pmcid">PMC7127386</pub-id></element-citation></ref><ref id="bib0490"><label>98</label><element-citation publication-type="journal" id="sbref0490"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A trial of Lopinavir&#8211;Ritonavir in adults hospitalized with severe Covid-19</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>19</issue><year>2020</year><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">32187464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmcid">PMC7121492</pub-id></element-citation></ref><ref id="bib0495"><label>99</label><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>C.-Y.</given-names></name><etal/></person-group><article-title>Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan</article-title><source>J. Microbiol. Immunol. Infect.</source><volume>53</volume><issue>3</issue><year>2020</year><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">32331982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmii.2020.03.032</pub-id><pub-id pub-id-type="pmcid">PMC7194913</pub-id></element-citation></ref><ref id="bib0500"><label>100</label><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection</article-title><source>J. Infect. Dis.</source><volume>221</volume><issue>10</issue><year>2020</year><fpage>1688</fpage><lpage>1698</lpage><pub-id pub-id-type="pmid">31822885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz656</pub-id></element-citation></ref><ref id="bib0505"><label>101</label><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name name-style="western"><surname>Simsek Yavuz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>S.</given-names></name></person-group><article-title>Antiviral treatment of COVID-19</article-title><source>Turk. J. Med. Sci.</source><volume>50</volume><issue>SI-1</issue><year>2020</year><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">32293834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3906/sag-2004-145</pub-id><pub-id pub-id-type="pmcid">PMC7195979</pub-id></element-citation></ref><ref id="bib0510"><label>102</label><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name name-style="western"><surname>Shrestha</surname><given-names>D.B.</given-names></name><etal/></person-group><article-title>Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis</article-title><source>Virol. J.</source><volume>17</volume><issue>1</issue><year>2020</year><comment>p. 141-141</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-020-01412-z</pub-id><pub-id pub-id-type="pmcid">PMC7512218</pub-id><pub-id pub-id-type="pmid">32972430</pub-id></element-citation></ref><ref id="bib0515"><label>103</label><element-citation publication-type="journal" id="sbref0515"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Experimental treatment with Favipiravir for COVID-19: an open-label control study</article-title><source>Engineering</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eng.2020.03.007</pub-id><pub-id pub-id-type="pmcid">PMC7185795</pub-id><pub-id pub-id-type="pmid">32346491</pub-id></element-citation></ref><ref id="bib0520"><label>104</label><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Favipiravir versus arbidol for COVID-19: a randomized clinical trial</article-title><source>MedRxiv</source><year>2020</year></element-citation></ref><ref id="bib0525"><label>105</label><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmcid">PMC7190303</pub-id><pub-id pub-id-type="pmid">32423584</pub-id></element-citation></ref><ref id="bib0530"><label>106</label><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of Covid-19 - final report</article-title><source>N. Engl. J. Med.</source><year>2020</year><comment>p. NEJMoa2007764</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmcid">PMC7262788</pub-id><pub-id pub-id-type="pmid">32445440</pub-id></element-citation></ref><ref id="bib0535"><label>107</label><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name name-style="western"><surname>Lamontagne</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A living WHO guideline on drugs for covid-19</article-title><source>BMJ</source><volume>370</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.m3379</pub-id><pub-id pub-id-type="pmid">32887691</pub-id></element-citation></ref><ref id="bib0540"><label>108</label><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name name-style="western"><surname>Ivashchenko</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa1176</pub-id><pub-id pub-id-type="pmcid">PMC7454388</pub-id><pub-id pub-id-type="pmid">32770240</pub-id></element-citation></ref><ref id="bib0545"><label>109</label><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19</article-title><source>Antimicrob. Agents Chemother.</source><volume>64</volume><issue>6</issue><year>2020</year><fpage>e00754</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">32312781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00754-20</pub-id><pub-id pub-id-type="pmcid">PMC7269515</pub-id></element-citation></ref><ref id="bib0550"><label>110</label><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: scientific rationale and review</article-title><source>Res. Pract. Thromb. Haemost.</source><volume>4</volume><issue>4</issue><year>2020</year><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">32542213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rth2.12357</pub-id><pub-id pub-id-type="pmcid">PMC7267116</pub-id></element-citation></ref><ref id="bib0555"><label>111</label><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name name-style="western"><surname>Rubbert-Roth</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A review of recent advances using tocilizumab in the treatment of rheumatic diseases</article-title><source>Rheumatol. Ther.</source><volume>5</volume><issue>1</issue><year>2018</year><fpage>21</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">29502236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40744-018-0102-x</pub-id><pub-id pub-id-type="pmcid">PMC5935615</pub-id></element-citation></ref><ref id="bib0560"><label>112</label><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name name-style="western"><surname>Alende-Castro</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases</article-title><source>J. Investig. Allergol. Clin. Immunol.</source><year>2020</year><comment>p. 0</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.18176/jiaci.0601</pub-id><pub-id pub-id-type="pmid">32500858</pub-id></element-citation></ref><ref id="bib0565"><label>113</label><element-citation publication-type="journal" id="sbref0565"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Tocilizumab in patients with severe COVID-19: a retrospective cohort study</article-title><source>Lancet Rheumatol.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2665-9913(20)30173-9</pub-id><pub-id pub-id-type="pmcid">PMC7314456</pub-id><pub-id pub-id-type="pmid">32835257</pub-id></element-citation></ref><ref id="bib0570"><label>114</label><element-citation publication-type="journal" id="sbref0570"><person-group person-group-type="author"><name name-style="western"><surname>Rosas</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Tocilizumab in hospitalized patients with COVID-19 pneumonia</article-title><source>medRxiv</source><year>2020</year><comment>p. 2020.08.27.20183442</comment></element-citation></ref><ref id="bib0575"><label>115</label><element-citation publication-type="journal" id="sbref0575"><person-group person-group-type="author"><name name-style="western"><surname>Castelli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cimini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>C.</given-names></name></person-group><article-title>Cytokine storm in COVID-19: "When you come out of the storm, you won&#8217;t Be the same person who walked in</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><comment>p. 2132-2132</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.02132</pub-id><pub-id pub-id-type="pmcid">PMC7492381</pub-id><pub-id pub-id-type="pmid">32983172</pub-id></element-citation></ref><ref id="bib0580"><label>116</label><element-citation publication-type="journal" id="sbref0580"><person-group person-group-type="author"><name name-style="western"><surname>Ledford</surname><given-names>H.</given-names></name></person-group><article-title>Coronavirus breakthrough: dexamethasone is first drug shown to save lives</article-title><source>Nature</source><volume>582</volume><issue>7813</issue><year>2020</year><fpage>469</fpage><pub-id pub-id-type="pmid">32546811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-01824-5</pub-id></element-citation></ref><ref id="bib0585"><label>117</label><element-citation publication-type="journal" id="sbref0585"><person-group person-group-type="author"><name name-style="western"><surname>Villar</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial</article-title><source>Lancet Respir. Med.</source><volume>8</volume><issue>3</issue><year>2020</year><fpage>267</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">32043986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(19)30417-5</pub-id></element-citation></ref><ref id="bib0590"><label>118</label><element-citation publication-type="journal" id="sbref0590"><person-group person-group-type="author"><name name-style="western"><surname>Horby</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Dexamethasone in hospitalized patients with Covid-19-Preliminary report</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmcid">PMC7383595</pub-id><pub-id pub-id-type="pmid">32678530</pub-id></element-citation></ref><ref id="bib0595"><label>119</label><element-citation publication-type="journal" id="sbref0595"><person-group person-group-type="author"><name name-style="western"><surname>Dequin</surname><given-names>P.-F.</given-names></name><etal/></person-group><article-title>Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial</article-title><source>JAMA</source><volume>324</volume><issue>13</issue><year>2020</year><fpage>1298</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">32876689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.16761</pub-id><pub-id pub-id-type="pmcid">PMC7489432</pub-id></element-citation></ref><ref id="bib0600"><label>120</label><element-citation publication-type="journal" id="sbref0600"><person-group person-group-type="author"><name name-style="western"><surname>Angus</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial</article-title><source>JAMA</source><volume>324</volume><issue>13</issue><year>2020</year><fpage>1317</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">32876697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.17022</pub-id><pub-id pub-id-type="pmcid">PMC7489418</pub-id></element-citation></ref><ref id="bib0605"><label>121</label><element-citation publication-type="journal" id="sbref0605"><person-group person-group-type="author"><name name-style="western"><surname>Annamaria</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eugenia</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Paolo</surname><given-names>S.</given-names></name></person-group><article-title>Anti-SARS-CoV-2 hyperimmune plasma workflow</article-title><source>Transfus. Apher. Sci.</source><year>2020</year><fpage>102850</fpage><pub-id pub-id-type="pmid">32540345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.transci.2020.102850</pub-id><pub-id pub-id-type="pmcid">PMC7283061</pub-id></element-citation></ref><ref id="bib0610"><label>122</label><element-citation publication-type="journal" id="sbref0610"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals</article-title><source>Sci. Adv.</source><year>2020</year><comment>p. eabc9999</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abc9999</pub-id><pub-id pub-id-type="pmcid">PMC7673700</pub-id><pub-id pub-id-type="pmid">33036961</pub-id></element-citation></ref><ref id="bib0615"><label>123</label><element-citation publication-type="book" id="sbref0615"><person-group person-group-type="author"><name name-style="western"><surname>Joyner</surname><given-names>M.J.</given-names></name><etal/></person-group><part-title>Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients</part-title><source>Mayo Clinic Proceedings</source><year>2020</year><publisher-name>Elsevier</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2020.06.028</pub-id><pub-id pub-id-type="pmcid">PMC7368917</pub-id><pub-id pub-id-type="pmid">32861333</pub-id></element-citation></ref><ref id="bib0620"><label>124</label><element-citation publication-type="journal" id="sbref0620"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2029849</pub-id><pub-id pub-id-type="pmcid">PMC7646625</pub-id><pub-id pub-id-type="pmid">33113295</pub-id></element-citation></ref><ref id="bib0625"><label>125</label><element-citation publication-type="journal" id="sbref0625"><person-group person-group-type="author"><name name-style="western"><surname>Zost</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title><source>Nature</source><volume>584</volume><issue>7821</issue><year>2020</year><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">32668443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2548-6</pub-id><pub-id pub-id-type="pmcid">PMC7584396</pub-id></element-citation></ref><ref id="bib0630"><label>126</label><element-citation publication-type="journal" id="sbref0630"><person-group person-group-type="author"><name name-style="western"><surname>Baum</surname><given-names>A.</given-names></name><etal/></person-group><article-title>REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters</article-title><source>Science</source><year>2020</year><comment>p. eabe2402</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abe2402</pub-id><pub-id pub-id-type="pmcid">PMC7857396</pub-id><pub-id pub-id-type="pmid">33037066</pub-id></element-citation></ref><ref id="bib0635"><label>127</label><element-citation publication-type="journal" id="sbref0635"><person-group person-group-type="author"><name name-style="western"><surname>Renn</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2</article-title><source>Trends Pharmacol. Sci.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2020.07.004</pub-id><pub-id pub-id-type="pmcid">PMC7572790</pub-id><pub-id pub-id-type="pmid">32829936</pub-id></element-citation></ref><ref id="bib0640"><label>128</label><element-citation publication-type="journal" id="sbref0640"><person-group person-group-type="author"><name name-style="western"><surname>Dearlove</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants</article-title><source>Proc. Natl. Acad. Sci.</source><volume>117</volume><issue>38</issue><year>2020</year><fpage>23652</fpage><lpage>23662</lpage><pub-id pub-id-type="pmid">32868447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2008281117</pub-id><pub-id pub-id-type="pmcid">PMC7519301</pub-id></element-citation></ref><ref id="bib0645"><label>129</label><element-citation publication-type="journal" id="sbref0645"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><issue>50</issue><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">18824060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.09.026</pub-id><pub-id pub-id-type="pmcid">PMC2612543</pub-id></element-citation></ref><ref id="bib0650"><label>130</label><element-citation publication-type="journal" id="sbref0650"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.T.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title><source>Antivir. Ther.</source><volume>12</volume><issue>7</issue><year>2007</year><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">18018769</pub-id></element-citation></ref><ref id="bib0655"><label>131</label><element-citation publication-type="journal" id="sbref0655"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>V.C.C.</given-names></name><etal/></person-group><article-title>Clinical management and infection control of SARS: lessons learned</article-title><source>Antiviral Res.</source><volume>100</volume><issue>2</issue><year>2013</year><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">23994190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2013.08.016</pub-id><pub-id pub-id-type="pmcid">PMC7132413</pub-id></element-citation></ref><ref id="bib0660"><label>132</label><element-citation publication-type="journal" id="sbref0660"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Stoffels</surname><given-names>P.</given-names></name></person-group><article-title>Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times</article-title><source>JAMA</source><volume>323</volume><issue>24</issue><year>2020</year><fpage>2455</fpage><lpage>2457</lpage><pub-id pub-id-type="pmid">32421150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.8920</pub-id></element-citation></ref><ref id="bib0665"><label>133</label><element-citation publication-type="journal" id="sbref0665"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>E.P.K.</given-names></name><name name-style="western"><surname>Shrotri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kampmann</surname><given-names>B.</given-names></name></person-group><article-title>Keeping track of the SARS-CoV-2 vaccine pipeline</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-00455-1</pub-id><pub-id pub-id-type="pmcid">PMC7521571</pub-id><pub-id pub-id-type="pmid">32989290</pub-id></element-citation></ref><ref id="bib0670"><label>134</label><element-citation publication-type="journal" id="sbref0670"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id><pub-id pub-id-type="pmid">33069281</pub-id></element-citation></ref><ref id="bib0675"><label>135</label><element-citation publication-type="journal" id="sbref0675"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.-J.</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial</article-title><source>medRxiv</source><year>2020</year><comment>p. 2020.07.31.20161216</comment></element-citation></ref><ref id="bib0680"><label>136</label><element-citation publication-type="journal" id="sbref0680"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title><source>JAMA</source><volume>324</volume><issue>10</issue><year>2020</year><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></element-citation></ref><ref id="bib0685"><label>137</label><element-citation publication-type="journal" id="sbref0685"><person-group person-group-type="author"><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion InactivatedSARS-CoV-2 vaccine - BBV152</article-title><source>bioRxiv</source><year>2020</year><comment>p. 2020.09.09.285445</comment></element-citation></ref><ref id="bib0690"><label>138</label><element-citation publication-type="book" id="sbref0690"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><etal/></person-group><part-title>Remarkable Immunogenicity and Protective Efficacy of BBV152, an Inactivated SARS-CoV-2 Vaccine in Rhesus Macaques</part-title><year>2020</year></element-citation></ref><ref id="bib0695"><label>139</label><element-citation publication-type="journal" id="sbref0695"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><issue>10</issue><year>2020</year><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">32887954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id></element-citation></ref><ref id="bib0700"><label>140</label><element-citation publication-type="journal" id="sbref0700"><person-group person-group-type="author"><name name-style="western"><surname>Poland</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 vaccine development: current status</article-title><source>Mayo Clin. Proc.</source><volume>95</volume><issue>10</issue><year>2020</year><fpage>2172</fpage><lpage>2188</lpage><pub-id pub-id-type="pmid">33012348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2020.07.021</pub-id><pub-id pub-id-type="pmcid">PMC7392072</pub-id></element-citation></ref><ref id="bib0705"><label>141</label><element-citation publication-type="journal" id="sbref0705"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>R.P.</given-names></name><etal/></person-group><article-title>Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19</article-title><source>Front. Pharmacol.</source><volume>11</volume><year>2020</year><fpage>1258</fpage><pub-id pub-id-type="pmid">32973505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.01258</pub-id><pub-id pub-id-type="pmcid">PMC7466451</pub-id></element-citation></ref><ref id="bib0710"><label>142</label><element-citation publication-type="journal" id="sbref0710"><person-group person-group-type="author"><name name-style="western"><surname>Hajj Hussein</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Vaccines through centuries: major cornerstones of global health</article-title><source>Front. Public Health</source><volume>3</volume><issue>269</issue><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2015.00269</pub-id><pub-id pub-id-type="pmcid">PMC4659912</pub-id><pub-id pub-id-type="pmid">26636066</pub-id></element-citation></ref><ref id="bib0715"><label>143</label><element-citation publication-type="journal" id="sbref0715"><person-group person-group-type="author"><name name-style="western"><surname>Nichol</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial</article-title><source>JAMA</source><volume>282</volume><issue>2</issue><year>1999</year><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">10411194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.282.2.137</pub-id></element-citation></ref><ref id="bib0720"><label>144</label><element-citation publication-type="journal" id="sbref0720"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><issue>7</issue><year>2020</year><fpage>427</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">32015473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-019-0261-1</pub-id><pub-id pub-id-type="pmcid">PMC10262260</pub-id></element-citation></ref><ref id="bib0725"><label>145</label><element-citation publication-type="journal" id="sbref0725"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Induction of mucosal immunity through systemic immunization: phantom or reality?</article-title><source>Hum. Vaccin. Immunother.</source><volume>12</volume><issue>4</issue><year>2016</year><fpage>1070</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">26752023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1114195</pub-id><pub-id pub-id-type="pmcid">PMC4962944</pub-id></element-citation></ref><ref id="bib0730"><label>146</label><element-citation publication-type="journal" id="sbref0730"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><etal/></person-group><article-title>Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement</article-title><source>bioRxiv</source><year>2020</year><comment>p. 2020.05.15.098079</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.09.061</pub-id><pub-id pub-id-type="pmcid">PMC7508514</pub-id><pub-id pub-id-type="pmid">33039209</pub-id></element-citation></ref><ref id="bib0735"><label>147</label><element-citation publication-type="journal" id="sbref0735"><person-group person-group-type="author"><name name-style="western"><surname>Capell</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Potential applications of plant biotechnology against SARS-CoV-2</article-title><source>Trends Plant Sci.</source><volume>25</volume><issue>7</issue><year>2020</year><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">32371057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tplants.2020.04.009</pub-id><pub-id pub-id-type="pmcid">PMC7181989</pub-id></element-citation></ref><ref id="bib0740"><label>148</label><element-citation publication-type="journal" id="sbref0740"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id><pub-id pub-id-type="pmid">32877576</pub-id></element-citation></ref><ref id="bib0745"><label>149</label><element-citation publication-type="journal" id="sbref0745"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name></person-group><article-title>Biomarkers of COVID-19 and technologies to combat SARS-CoV-2</article-title><source>Adv. Biomarker Sci. Technol.</source><volume>2</volume><year>2020</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.abst.2020.08.001</pub-id><pub-id pub-id-type="pmcid">PMC7435336</pub-id><pub-id pub-id-type="pmid">33511330</pub-id></element-citation></ref><ref id="bib0750"><label>150</label><element-citation publication-type="journal" id="sbref0750"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>Merck, one of Big Pharma&#8217;s biggest players, reveals its COVID-19 vaccine and therapy plans</article-title><source>Science</source><year>2020</year></element-citation></ref><ref id="bib0755"><label>151</label><element-citation publication-type="journal" id="sbref0755"><person-group person-group-type="author"><name name-style="western"><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>Replicating and non-replicating viral vectors for vaccine development</article-title><source>Curr. Opin. Biotechnol.</source><volume>18</volume><issue>6</issue><year>2007</year><fpage>546</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">18063357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.copbio.2007.10.010</pub-id><pub-id pub-id-type="pmcid">PMC2245896</pub-id></element-citation></ref><ref id="bib0760"><label>152</label><element-citation publication-type="journal" id="sbref0760"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D.Y.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</article-title><source>Lancet</source><volume>396</volume><issue>10255</issue><year>2020</year><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="bib0765"><label>153</label><element-citation publication-type="journal" id="sbref0765"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>Nature</source><volume>586</volume><issue>7830</issue><year>2020</year><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">32731258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id></element-citation></ref><ref id="bib0770"><label>154</label><element-citation publication-type="journal" id="sbref0770"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.-C.</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><volume>396</volume><issue>10249</issue><year>2020</year><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></element-citation></ref><ref id="bib0775"><label>155</label><element-citation publication-type="journal" id="sbref0775"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial</article-title><source>medRxiv</source><year>2020</year><comment>p. 2020.09.23.20199604</comment></element-citation></ref><ref id="bib0780"><label>156</label><element-citation publication-type="journal" id="sbref0780"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><volume>396</volume><issue>10249</issue><year>2020</year><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></element-citation></ref><ref id="bib0785"><label>157</label><element-citation publication-type="journal" id="sbref0785"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Direct gene transfer into mouse muscle in vivo</article-title><source>Science</source><volume>247</volume><issue>4949</issue><year>1990</year><fpage>1465</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">1690918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1690918</pub-id></element-citation></ref><ref id="bib0790"><label>158</label><element-citation publication-type="journal" id="sbref0790"><person-group person-group-type="author"><name name-style="western"><surname>Fuller</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>P.</given-names></name></person-group><article-title>Amplifying RNA vaccine development</article-title><source>N. Engl. J. Med.</source><volume>382</volume><issue>25</issue><year>2020</year><fpage>2469</fpage><lpage>2471</lpage><pub-id pub-id-type="pmid">32558474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMcibr2009737</pub-id></element-citation></ref><ref id="bib0795"><label>159</label><element-citation publication-type="journal" id="sbref0795"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>mRNA as a transformative technology for vaccine development to control infectious diseases</article-title><source>Mol. Ther.</source><volume>27</volume><issue>4</issue><year>2019</year><fpage>757</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">30803823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.01.020</pub-id><pub-id pub-id-type="pmcid">PMC6453507</pub-id></element-citation></ref><ref id="bib0800"><label>160</label><element-citation publication-type="journal" id="sbref0800"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title><source>Nature</source><volume>586</volume><issue>7830</issue><year>2020</year><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">32998157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2814-7</pub-id></element-citation></ref><ref id="bib0805"><label>161</label><element-citation publication-type="journal" id="sbref0805"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><etal/></person-group><article-title>RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study</article-title><source>medRxiv</source><year>2020</year><comment>p. 2020.08.17.20176651</comment></element-citation></ref><ref id="bib0810"><label>162</label><element-citation publication-type="journal" id="sbref0810"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><volume>586</volume><issue>7830</issue><year>2020</year><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">32785213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id></element-citation></ref><ref id="bib0815"><label>163</label><element-citation publication-type="journal" id="sbref0815"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>C.-L.</given-names></name><etal/></person-group><article-title>Structure-based design of prefusion-stabilized SARS-CoV-2 spikes</article-title><source>Science</source><volume>369</volume><issue>6510</issue><year>2020</year><fpage>1501</fpage><lpage>1505</lpage><pub-id pub-id-type="pmid">32703906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd0826</pub-id><pub-id pub-id-type="pmcid">PMC7402631</pub-id></element-citation></ref><ref id="bib0820"><label>164</label><element-citation publication-type="journal" id="sbref0820"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>An mRNA vaccine against SARS-CoV-2 &#8212; preliminary report</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id><pub-id pub-id-type="pmid">32663912</pub-id></element-citation></ref><ref id="bib0825"><label>165</label><element-citation publication-type="journal" id="sbref0825"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2028436</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id><pub-id pub-id-type="pmid">32991794</pub-id></element-citation></ref><ref id="bib0830"><label>166</label><element-citation publication-type="journal" id="sbref0830"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccines-how far from clinical use?</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><issue>11</issue><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id><pub-id pub-id-type="pmid">30445702</pub-id></element-citation></ref><ref id="bib0835"><label>167</label><element-citation publication-type="journal" id="sbref0835"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation</article-title><source>Gene Ther.</source><volume>11</volume><issue>8</issue><year>2004</year><fpage>711</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">14724672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.gt.3302213</pub-id></element-citation></ref><ref id="bib0840"><label>168</label><element-citation publication-type="journal" id="sbref0840"><person-group person-group-type="author"><name name-style="western"><surname>Brisse</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Emerging concepts and technologies in vaccine development</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><comment>p. 583077-583077</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.583077</pub-id><pub-id pub-id-type="pmcid">PMC7554600</pub-id><pub-id pub-id-type="pmid">33101309</pub-id></element-citation></ref><ref id="bib0845"><label>169</label><element-citation publication-type="journal" id="sbref0845"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>T.R.F.</given-names></name><etal/></person-group><article-title>Immunogenicity of a DNA vaccine candidate for COVID-19</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>2601</fpage><pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></element-citation></ref><ref id="bib0850"><label>170</label><element-citation publication-type="journal" id="sbref0850"><person-group person-group-type="author"><name name-style="western"><surname>Kern</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs</article-title><source>bioRxiv</source><year>2020</year><comment>p. 2020.06.17.156554</comment></element-citation></ref><ref id="bib0855"><label>171</label><element-citation publication-type="journal" id="sbref0855"><person-group person-group-type="author"><name name-style="western"><surname>Konno</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant</article-title><source>bioRxiv</source><year>2020</year><comment>p. 2020.05.11.088179</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108185</pub-id><pub-id pub-id-type="pmcid">PMC7473339</pub-id><pub-id pub-id-type="pmid">32941788</pub-id></element-citation></ref><ref id="bib0860"><label>172</label><element-citation publication-type="journal" id="sbref0860"><person-group person-group-type="author"><name name-style="western"><surname>Holland</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>An 81 nucleotide deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (jan-Mar 2020)</article-title><source>J. Virol.</source><year>2020</year><comment>p. JVI.00711-00720</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00711-20</pub-id><pub-id pub-id-type="pmcid">PMC7343219</pub-id><pub-id pub-id-type="pmid">32357959</pub-id></element-citation></ref><ref id="bib0865"><label>173</label><element-citation publication-type="book" id="sbref0865"><person-group person-group-type="author"><name name-style="western"><surname>CHAKRABORTY</surname><given-names>A.K.</given-names></name></person-group><part-title>Coronavirus Nsp2 Protein Homologies to the Bacterial DNA Topoisomerase I and IV Suggest Nsp2 Protein Is a Unique RNA Topoisomerase With Novel Target for Drug and Vaccine Development</part-title><year>2020</year></element-citation></ref><ref id="bib0870"><label>174</label><element-citation publication-type="journal" id="sbref0870"><person-group person-group-type="author"><name name-style="western"><surname>Yoshimoto</surname><given-names>F.K.</given-names></name></person-group><article-title>The proteins of severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19</article-title><source>Protein J.</source><year>2020</year><fpage>1</fpage><pub-id pub-id-type="pmid">32447571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10930-020-09901-4</pub-id><pub-id pub-id-type="pmcid">PMC7245191</pub-id></element-citation></ref></ref-list><bio><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fx1_lrg.jpg"/><p><bold>Professor Moiz Bakhiet</bold> is the CEO (Founder) of Princess Al-Jawhara Center for Molecular Medicine and Genetics. He is the Chairman of the Department of Molecular Medicine, College of Medicine, Arabian Gulf University. He is a Senior Consultant / Physician Neurologist at the University Medical Center, King Abdulla Medical City, Bahrain. He obtained his M.B.B.S at the Faculty of Medicine at the University of Khartoum and his Ph.D. at the Karolinska Institute, Stockholm, Sweden.</p></bio><bio><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fx2_lrg.jpg"/><p><bold>Sebastien Taurin</bold> obtained his Ph.D. in Biomedical Sciences at the University of Montreal, Canada, in 2003. He is currently an Associate Professor at the Arabian Gulf University in the Department of Molecular Medicine. His main research interests are breast cancers, stem cells, inflammation, and microbiome.</p></bio></back></article></pmc-articleset>